Archives: Guidelines

Empiric Antibiotic Selector

💊 Empiric Antibiotic Selector

Risk-stratified empiric therapy — a starting point, not a substitute for the local antibiogram or ID consult

Reviewed by the DosePilot Medical Team · Last medically reviewed: June 2026

Choose the single most likely source. For multiple or unclear sources, use “Undifferentiated sepsis”.

Severity sets urgency (time-to-antibiotic), escalation thresholds, and IV-vs-oral; spectrum also depends on source and resistance risk — review the conditional prompts. “Stable” enables narrower, oral-switch-friendly therapy.

Empiric Recommendation

Before you prescribe

⛔ Not for: meningitis / CNS infection · pediatrics / neonates · pregnancy · infective endocarditis. Adults, normal renal function only.

  1. Draw blood cultures (≥ 2 sets) + site cultures before the first dose — but do not delay antibiotics beyond the time target if cultures cannot be obtained promptly (especially in shock).
  2. Time-to-antibiotic: septic shock / probable sepsis ≤ 1 h; possible sepsis ≤ 3 h.
  3. Source control (drainage / line removal / debridement) is as important as antibiotics.
  4. Reassess at 48–72 h: de-escalate on culture & susceptibility; stop if infection excluded.
  5. This is an empiric starting point — substitute your local antibiogram & institutional protocol; consult ID for CRE, DTR-Pseudomonas, persistent S. aureus bacteremia / candidemia, and complex cases.

⚠️ Scope

Adults with normal renal function. Not for meningitis / CNS infection, pediatrics / neonates, pregnancy, or infective endocarditis (use dedicated guidance for endocarditis). Single primary site (use “Undifferentiated sepsis” for multiple/unclear). Adjust every dose for renal function, weight, and therapeutic drug monitoring.

Recent Updates

  • Every regimen card now lists an evidence-based alternative agent for when the first choice can’t be used (intolerance, toxicity, or shortage) — e.g., cefotaxime or a respiratory fluoroquinolone for ceftriaxone, imipenem-cilastatin for meropenem, and linezolid or daptomycin (by site) for vancomycin. Deep-resistant niches show “no equivalent — ID consult”.
  • Empiric coverage follows a risk-stratified philosophy (Surviving Sepsis Campaign 2026): even in shock, MRSA, double Gram-negative, and antifungal coverage are not routine — add them only when risk factors are present.
  • The first-ever IDSA 2025 complicated-UTI guideline and the SIS 2024 intra-abdominal guideline now govern those sites; for invasive ESBL infection, avoid piperacillin-tazobactam (MERINO). For metallo-β-lactamase–producing CRE, fixed-dose aztreonam-avibactam is now FDA-approved (2025).
  • Penicillin allergy reframed: true cephalosporin cross-reactivity is ~1–2% (not 10%); side-chain–different cephalosporins and carbapenems are safe in most patients.

Source: Prescott HC, et al. Surviving Sepsis Campaign 2026; Trautner BW, et al. IDSA cUTI 2025; Carmeli Y, et al. REVISIT (aztreonam-avibactam) 2025; Khan DA, et al. Drug Allergy Practice Parameter 2022; Tamma PD, et al. IDSA AMR Gram-negative 2024; Liu C, et al. IDSA MRSA 2011; Stevens DL, et al. IDSA SSTI 2014. (See Sources.)

Key Knowledge Points

  • Correctly identifying the likely source is the single most important driver of empiric choice.
  • Cultures before antibiotics, then de-escalate at 48–72 h — empiric therapy is meant to be narrowed.
  • Resistance coverage should track risk factors and local prevalence, not reflex broad-spectrum use.
  • Doses shown are normal-renal-function adult starting doses — always adjust for the individual patient.

About This Tool

The Empiric Antibiotic Selector suggests a reasonable empiric regimen — the antibiotics to start before culture results return — based on the infection site, where it was acquired, known colonization, host factors, and β-lactam allergy. It distills current IDSA, ATS, SIS, and Surviving Sepsis Campaign guidance into a single workflow, emphasizing antibiotic stewardship: cover the likely pathogens, avoid unnecessary breadth, and narrow therapy as soon as data allow.

How to Use This Tool

  1. Select the infection site — the primary driver of likely pathogens.
  2. Set acquisition (community vs hospital/healthcare) — this distinguishes CAP from HAP/VAP and raises the resistance tier.
  3. Flag known colonization or prior resistant isolates (select all that apply).
  4. Mark host and severity (immunocompromised/neutropenic; septic shock) and any β-lactam allergy.
  5. Review the regimen, the conditional add-on prompts, and the always-do steps.

Frequently Asked Questions (FAQ)

1. Is this tool a substitute for a local antibiogram or an ID consult?

No. It provides a reasonable empiric starting point, but local resistance patterns vary widely. Always substitute your institution’s antibiogram and protocols, and consult Infectious Diseases for resistant organisms (CRE, DTR-Pseudomonas), persistent S. aureus bacteremia or candidemia, and complex cases.

2. Why doesn’t septic shock automatically add MRSA, double Gram-negative, or antifungal coverage?

The 2026 Surviving Sepsis Campaign recommends risk stratification rather than reflexive broad coverage. Unnecessary anti-MRSA, dual Gram-negative, or antifungal therapy increases toxicity, C. difficile, resistance, and acute kidney injury without improving outcomes. Add each only when specific risk factors are present.

3. My patient reports a penicillin allergy. Can I still use a cephalosporin or carbapenem?

In most cases, yes. True cross-reactivity is about 1–2% (not the historically quoted 10%), and under 1% for cephalosporins with a different side chain. For non-severe or unconfirmed allergy, cephalosporins and carbapenems can be used as-is. Even after anaphylaxis to penicillin, a side-chain–different cephalosporin or a carbapenem is generally safe. Reserve aztreonam-based regimens for the rare patient who must avoid all β-lactams.

4. Should I treat ESBL infection with piperacillin-tazobactam?

Not for invasive infection. The MERINO trial showed higher mortality with piperacillin-tazobactam than meropenem for ESBL bloodstream infection. Use a carbapenem (ertapenem if stable; meropenem if severe, ICU, or low albumin). For ESBL complicated UTI, oral TMP-SMX or a fluoroquinolone is preferred if susceptible.

5. How long should empiric therapy continue?

Empiric therapy is meant to be temporary. Obtain cultures before the first dose, reassess at 48–72 hours, and de-escalate to the narrowest effective agent once susceptibility data return. Many infections now have evidence-based short courses, and IV-to-oral switch is appropriate once the patient is stable.

Related Tools

📖 Sources:

  1. Metlay JP, et al. (2019). Diagnosis and treatment of adults with community-acquired pneumonia (ATS/IDSA). Am J Respir Crit Care Med. PMID 31573350.
  2. Jones BE, et al. (2025). ATS community-acquired pneumonia guideline (2025 update; ATS-only). Am J Respir Crit Care Med. PMID 40679934.
  3. Kalil AC, et al. (2016). Management of adults with hospital-acquired and ventilator-associated pneumonia. Clin Infect Dis. PMID 27418577.
  4. Trautner BW, et al. (2025). IDSA 2025 guideline on the management and treatment of complicated urinary tract infections: selection of antibiotic therapy. Clin Infect Dis. doi:10.1093/cid/ciaf460. PMID 41419213.
  5. Hooton TM, et al. (2010). Diagnosis, prevention, and treatment of catheter-associated UTI (IDSA). Clin Infect Dis. PMID 20175247.
  6. Nicolle LE, et al. (2019). IDSA guideline for the management of asymptomatic bacteriuria. Clin Infect Dis. PMID 30895288.
  7. Huston JM, et al. (2024). Surgical Infection Society revised guidelines on intra-abdominal infection. Surg Infect. PMID 38990709.
  8. Bonomo RA, et al. (2024). 2024 IDSA clinical practice guideline update on complicated intra-abdominal infections: risk assessment, diagnostic imaging, and microbiological evaluation. Clin Infect Dis. 79(Suppl 3):S81–S87. PMID 38965057.
  9. Stevens DL, et al. (2014). IDSA practice guidelines for skin and soft tissue infections. Clin Infect Dis. PMID 24973422.
  10. Mermel LA, et al. (2009). IDSA guidelines for intravascular catheter-related infection. Clin Infect Dis. PMID 19489710.
  11. Prescott HC, et al. (2026). Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026. Crit Care Med. 54(4):725–812. doi:10.1097/CCM.0000000000007075; PMID 41869847.
  12. Freifeld AG, et al. (2011). IDSA guideline for use of antimicrobials in neutropenic patients with cancer. Clin Infect Dis. PMID 21258094.
  13. Taplitz RA, et al. (2018). ASCO/IDSA outpatient management of fever and neutropenia. J Clin Oncol. PMID 29461916.
  14. Tamma PD, et al. (2024). IDSA guidance on treatment of antimicrobial-resistant Gram-negative infections. Clin Infect Dis. PMID 39108079.
  15. Carmeli Y, et al. (2025). Aztreonam-avibactam versus meropenem for serious Gram-negative infections (REVISIT): a phase 3 randomised trial. Lancet Infect Dis. 25(2):218–230. PMID 39389071.
  16. Liu C, et al. (2011). IDSA guideline for treatment of MRSA infections. Clin Infect Dis. PMID 21208910.
  17. Rybak MJ, et al. (2020). Therapeutic monitoring of vancomycin (AUC-guided consensus). Am J Health-Syst Pharm. doi:10.1093/ajhp/zxaa036.
  18. Harris PNA, et al. (2018). Piperacillin-tazobactam vs meropenem for ESBL bloodstream infection (MERINO). JAMA. PMID 30208454.
  19. Pappas PG, et al. (2016). IDSA clinical practice guideline for the management of candidiasis. Clin Infect Dis. PMID 26679628.
  20. Cornely OA, et al. (2025). Global guideline for the diagnosis and management of candidiasis. Lancet Infect Dis. doi:10.1016/S1473-3099(24)00749-7.
  21. Khan DA, et al. (2022). Drug allergy: a 2022 practice parameter update. J Allergy Clin Immunol. PMID 36122788.
  22. Trubiano JA, et al. (2020). Development and validation of the PEN-FAST penicillin allergy decision rule. JAMA Intern Med. PMID 32176248.
  23. Baddour LM, et al. (2015). Infective endocarditis in adults (AHA scientific statement). Circulation. PMID 26373316.
  24. Parente DM, et al. (2018). Clinical utility of MRSA nasal screening to rule out MRSA pneumonia (diagnostic meta-analysis). Clin Infect Dis. 67(1):1–7. PMID 29340593.
  25. Schuetz P, et al. (2017). Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections (Cochrane). Cochrane Database Syst Rev. 10:CD007498. PMID 29025194.

⚠️ Disclaimer:

This tool is for educational purposes and is not a substitute for professional clinical judgment. All treatment decisions must be made by a qualified clinician considering the individual patient’s full clinical context and local resistance data. Doses are normal-renal-function adult starting doses and must be adjusted for the individual patient.

DosePilot Logo

Powered by DosePilot.com

Bacterial Meningitis: Diagnosis & Empiric Therapy

🧠 Bacterial Meningitis — Diagnosis & Empiric Therapy

Adults with suspected acute bacterial meningitis — a time-critical starting point, not a substitute for the local antibiogram or ID consult

Reviewed by the DosePilot Medical Team · Last medically reviewed: June 2026

⏱ Time-critical

Give antibiotics + dexamethasone within ~1 hour of suspicion — do not delay for CT or LP. Draw blood cultures first; if a CT is needed before LP, give dexamethasone and antibiotics before the scan.

① CT head before lumbar puncture?

Image first if any of these is present (otherwise proceed straight to LP):

  • Age ≥ 60 years
  • Immunocompromised state
  • History of CNS disease (mass lesion, stroke, focal infection)
  • New-onset seizure (within 1 week)
  • Papilledema
  • Abnormal level of consciousness (unable to follow two consecutive commands; any GCS < 15)
  • Focal neurologic deficit (excluding isolated cranial nerve palsy)

Absence of all of the above has ~97% negative predictive value for a normal CT. If LP is delayed for imaging, antibiotics + dexamethasone must still go in within the time target.

② CSF interpretation (typical patterns)

BacterialViral / aseptic
Opening pressure↑ (often > 180–300 mm H₂O)Normal / mildly ↑
WBCTypically 1,000–5,000/µL (range <100 to >10,000), neutrophilic< 250/µL, lymphocytic
Glucose (CSF:serum)Low, < 40 mg/dL (ratio < 0.4)Normal
ProteinHigh (> 100–200 mg/dL)Normal / mildly ↑
Gram stainPositive in ~60–90%Negative

No single value rules meningitis in or out — bacterial meningitis can present with only modestly elevated or even near-normal CSF WBC early, when partially treated, or in neutropenia. Send Gram stain, culture, glucose, protein, cell count, and pathogen PCR; pair with 2 sets of blood cultures.

Empiric Management

Before you prescribe

  1. Blood cultures × 2 + CSF (Gram stain, culture, cell count, glucose, protein, PCR) — but do not delay antibiotics.
  2. Dexamethasone before / with the first antibiotic dose (see below).
  3. Doses shown are CNS (meningitis) doses for normal renal function — higher than usual systemic doses.
  4. Notify public health and give droplet precautions for suspected meningococcus; arrange chemoprophylaxis for close contacts.

⚠️ Scope

Adults with suspected community or healthcare-associated bacterial meningitis. Not for neonates / children, viral / aseptic, tuberculous, or fungal meningitis, and not a substitute for an ID consult. Confirm choices against your local antibiogram and resistance rates.

Recent Updates

  • The first global WHO 2025 meningitis guidelines recommend IV ceftriaxone or cefotaxime first-line (strong), adding ampicillin/amoxicillin when Listeria risk factors are present (strong), and considering vancomycin where pneumococcal penicillin/cephalosporin resistance is prevalent (conditional; rifampicin is an alternative).
  • Dexamethasone should be given before or with the first antibiotic dose; the mortality and disability benefit is greatest in pneumococcal meningitis (de Gans & van de Beek, NEJM 2002).
  • A CT head before LP is reserved for specific risk features — routine imaging only delays life-saving antibiotics.

Source: WHO Guidelines on Meningitis Diagnosis, Treatment and Care 2025; van de Beek D, et al. ESCMID 2016; Tunkel AR, et al. IDSA 2004. (See Sources.)

Key Knowledge Points

  • Antibiotics and dexamethasone within ~1 hour — never delay for imaging or LP.
  • Meningitis requires CNS-penetrating doses, higher and more frequent than usual systemic doses.
  • Add ampicillin for Listeria when age ≥ 50, immunocompromised, pregnant, or alcohol use disorder.
  • De-escalate to pathogen-directed therapy once Gram stain, culture, and susceptibilities return; stop dexamethasone if not pneumococcal.

About This Tool

This tool supports the first hour of managing an adult with suspected acute bacterial meningitis: deciding whether to image before lumbar puncture, interpreting the CSF, and choosing empiric antibiotics with CNS-penetrating doses plus adjunctive dexamethasone. It distills IDSA, ESCMID, and WHO guidance into one workflow. Empiric therapy is a bridge to pathogen-directed treatment — narrow it as soon as cultures and susceptibilities allow.

How to Use This Tool

  1. Use the CT-before-LP checklist and start antibiotics + dexamethasone without delay.
  2. Select the host / clinical setting — this sets Listeria and Gram-negative coverage.
  3. Flag a severe β-lactam allergy or encephalitis features if present.
  4. Review the regimen, the CNS doses, dexamethasone, and the always-do steps.
  5. Adjust every maintenance dose for renal function and monitor vancomycin by AUC.

Frequently Asked Questions (FAQ)

1. Should I delay antibiotics until after the LP or CT?

No. Give antibiotics with dexamethasone within about one hour; do not wait for imaging or LP. If CT is needed first, draw blood cultures and give dexamethasone plus antibiotics before the scan. CSF cultures may still be informative for several hours after the first dose.

2. Who needs a CT head before LP?

Image first for age ≥ 60, immunocompromise, a history of CNS disease, new-onset seizure (within a week), papilledema, abnormal consciousness (inability to follow two consecutive commands; any GCS < 15), or a focal neurologic deficit (excluding isolated cranial nerve palsy). Without these, the chance of an abnormal CT is very low and LP can proceed.

3. When do I add ampicillin?

When there is a risk factor for Listeria monocytogenes: age 50 or older, pregnancy, immunocompromise, or alcohol use disorder. Cephalosporins and vancomycin do not cover Listeria.

4. How is dexamethasone dosed, and when do I stop it?

Dexamethasone 10 mg IV every 6 hours for 4 days, started just before or with the first antibiotic dose. Continue the course if pneumococcus is confirmed or remains the leading suspect (including culture-negative cases); stop it if a non-pneumococcal organism is identified, and generally avoid it in confirmed Listeria. The benefit is established mainly in high-income settings and pneumococcal disease; WHO 2025 advises against routine use during meningococcal epidemics.

5. Why are the doses higher than usual?

The blood-brain barrier limits drug entry, so meningitis needs higher, more frequent dosing (e.g., ceftriaxone 2 g q12h). Give full empiric and loading doses regardless of renal function; adjust maintenance for renal function — usually by extending the interval rather than cutting the dose — and use AUC-guided vancomycin.

Related Tools

📖 Sources:

  1. Tunkel AR, et al. (2004). Practice guidelines for the management of bacterial meningitis (IDSA). Clin Infect Dis. PMID 15494903.
  2. Tunkel AR, et al. (2017). 2017 IDSA clinical practice guidelines for healthcare-associated ventriculitis and meningitis. Clin Infect Dis. 64(6):e34–e65. PMID 28203777.
  3. van de Beek D, et al. (2016). ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect. PMID 27062097.
  4. World Health Organization (2025). WHO guidelines on meningitis diagnosis, treatment and care. Geneva: WHO; 10 April 2025. ISBN 978-92-4-010804-2.
  5. de Gans J, van de Beek D (2002). Dexamethasone in adults with bacterial meningitis. N Engl J Med. PMID 12432041.
  6. Hasbun R, et al. (2001). Computed tomography of the head before lumbar puncture in adults with suspected meningitis. N Engl J Med. 345(24):1727–33. PMID 11742046.
  7. van de Beek D, et al. (2016). Community-acquired bacterial meningitis (review). Nat Rev Dis Primers. 2:16074. PMID 27808261.
  8. Brouwer MC, et al. (2010). Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. Clin Microbiol Rev. 23(3):467–92. PMID 20610819.
  9. Tunkel AR, et al. (2008). The management of encephalitis: clinical practice guidelines (IDSA). Clin Infect Dis. 47(3):303–27. PMID 18582201.

⚠️ Disclaimer:

This tool is for educational purposes and is not a substitute for professional clinical judgment. Suspected bacterial meningitis is an emergency; management must be individualized by a qualified clinician using the full clinical picture, local resistance data, and specialist input. Doses are CNS (meningitis) doses for normal-renal-function adults and must be adjusted for the individual patient.

DosePilot Logo

Powered by DosePilot.com

Intracranial Pressure (ICP) Management Guideline

ICP management guideline calculator in action
🧠 Intracranial Pressure (ICP) Management Guideline

Tiered ICP Management Protocol with Osmotherapy Dosing Calculator

Reviewed by the DosePilot Medical Team · Last medically reviewed: June 2026

—
Tier 0 — Baseline Neuroprotective Measures
🛏 Head of Bed & Positioning

• Elevate head of bed 30° (reduces ICP by improving venous drainage)

• Maintain head midline position — avoid neck flexion/rotation (prevents jugular venous compression)

• Loosen cervical collar if present

🌡 Temperature Control

• Target normothermia (36–37.5°C)

• Actively prevent and treat fever (each 1°C above 37°C increases cerebral metabolic demand by ~8%)

• Acetaminophen 1g IV q6h + cooling blanket/device as needed

💨 Ventilation & Oxygenation

• Target PaCO₂ 35–40 mmHg (low-normal eucapnia)

• Avoid hypoxia: SpO₂ ≥ 94%, PaO₂ ≥ 60 mmHg

• Avoid high PEEP (>12 cmH₂O) unless required for oxygenation — may impede cerebral venous return

⚠ Caution: Avoid hyperventilation (PaCO₂ <35) in Tier 0. Cerebral vasoconstriction reduces CBF and may worsen ischemia, especially within the first 24 hours post-injury.
💤 Sedation & Analgesia

• Propofol 20–50 mcg/kg/min OR Midazolam 0.02–0.1 mg/kg/hr for sedation

• Fentanyl 0.5–2 mcg/kg/hr OR Remifentanil for analgesia

• Target RASS −1 to −2 initially (deepen to −3 to −5 in Tier 1 if needed)

⚠ Propofol: Max <5 mg/kg/hr. Monitor for propofol infusion syndrome (PRIS) with prolonged use >48h — check triglycerides, CK, lactate. Contraindicated in egg/soy allergy.
❤ Hemodynamic Targets (CPP)

• Target CPP 60–70 mmHg (CPP = MAP − ICP)

• If ICP not monitored: target MAP ≥ 80 mmHg (ACS TBI 2024)

• Avoid CPP >70 mmHg aggressively — increases ARDS risk (BTF Level II)

• Avoid hypotension (SBP <90 mmHg) — a single episode doubles mortality

• Use norepinephrine as first-line vasopressor if MAP support is needed

⚡ Seizure Prophylaxis

• Levetiracetam 500–1000 mg IV q12h (preferred) OR Phenytoin (loading 20 mg/kg)

• Recommended for 7 days post-TBI to prevent early post-traumatic seizures

• Consider continuous EEG if comatose — up to 1/3 of patients have non-convulsive seizures

📉 Glucose Control & Nutrition

• Target glucose 140–180 mg/dL — avoid tight glycemic control (<110) in TBI (increases metabolic distress)

• Avoid hyperglycemia >200 mg/dL

• Initiate early enteral nutrition within 24–48 hours if possible

💧 Fluid & Hemoglobin Targets

• Maintain euvolemia with isotonic crystalloid (0.9% NaCl or balanced solution)

• Avoid hypotonic fluids (D5W, 0.45% NaCl) — worsens cerebral edema

• Hemoglobin transfusion threshold: ≥ 7 g/dL (ACS TBI 2024; liberal transfusion has not improved neurological outcomes)

📊 ICP Monitoring

• EVD (External Ventricular Drain): gold standard — allows both monitoring and therapeutic CSF drainage

• Intraparenchymal monitor: alternative when EVD placement not feasible

• Indications: GCS 3–8 with abnormal CT, or normal CT with ≥2 of: age >40, motor posturing, SBP <90

• Treatment threshold: ICP >20–22 mmHg

Tier 1 — First-Line ICP-Lowering Therapies
💧 CSF Drainage via EVD

• If EVD in place: open to drain at 10–15 cmH₂O for intermittent or continuous drainage

• Monitor CSF output (typically drain 5–10 mL when ICP rises above threshold)

• Watch for ventriculostomy-related infection (incidence 5–15%)

⚠ Caution: Risk of ventriculitis, hemorrhage during placement, over-drainage leading to slit ventricle. Do not drain against collapsed ventricles.
💤 Deepen Sedation

• Increase sedation depth to RASS −3 to −5 (unarousable)

• Reduces cerebral metabolic rate and thus ICP

💊 Osmotherapy Select Agent Below

Select an osmotherapy agent to view dosing, contraindications, and monitoring:

Mannitol 20% — 0.25–1 g/kg IV bolus over 15–20 min

Onset: 15–30 min | Duration: 1.5–6 hours | Repeat: q4–6h PRN

Osmotic reflection coefficient: 0.9 (partial BBB permeability → risk of rebound ICP with prolonged use)

Practical tip: Usually stocked as 12.5g bottles. 50g (250 mL of 20%) is a reasonable dose for CNS emergency en route to OR.

⚠ Contraindications & Cautions:
• Serum osmolality ≥320 mOsm/kg — risk of AKI, CNS toxicity (mandatory check before each dose)
• Hypovolemia / Hypotension — osmotic diuresis worsens dehydration; ensure euvolemia first
• Active intracranial hemorrhage (uncontrolled) — reduced viscosity may increase bleeding
• Compromised BBB — mannitol leaks into parenchyma causing rebound edema
• Anuria / severe renal failure — accumulation risk (half-life extends to 6–48h)
• Decompensated heart failure — initial volume expansion may precipitate pulmonary edema
• Known hypersensitivity to mannitol
✅ Monitoring:
• Serum osmolality q4–6h (hold if ≥320 mOsm/kg)
• Serum Na⁺, K⁺, BUN/Cr, I&O (aggressive diuresis → replace losses)
• Osmol gap: if >20 mOsm/kg, use with caution; if >55, contraindicated
• Avoid abrupt discontinuation after prolonged use — taper to prevent rebound ICP
3% NaCl — 150–250 mL IV bolus over 10–20 min (or 2–5 mL/kg)

Onset: Minutes | Duration: 2–6 hours | Repeat: q4–6h PRN

Osmotic reflection coefficient: 1.0 (does not cross intact BBB → no rebound effect)

Advantage over mannitol: No diuresis → maintains hemodynamic stability and CPP. Can be given peripherally.

Continuous infusion option: 0.5–1 mL/kg/hr, titrate to target Na⁺ 145–155 mEq/L.

⚠ Contraindications & Cautions:
• Serum Na⁺ ≥155–160 mEq/L — risk of central pontine myelinolysis, worsened hypernatremia
• Decompensated CHF — volume expansion may precipitate pulmonary edema
• Severe hyperchloremic metabolic acidosis — high chloride load exacerbates acidosis
• Hyponatremia correction >8–10 mEq/L/24h — risk of osmotic demyelination syndrome (ODS)
• Peripheral line caution: Safe for bolus at 3% concentration, but monitor IV site for phlebitis/extravasation
✅ Monitoring:
• Serum Na⁺ q4–6h (target 145–155 mEq/L; do not exceed 160)
• Serum Cl⁻, osmolality, fluid balance
• If on continuous infusion: taper gradually when discontinuing — do not abruptly stop
• Monitor IV site if peripheral — extravasation of HTS can cause tissue necrosis
23.4% NaCl — 30 mL IV bolus over 10–20 min via central line ONLY

Onset: Minutes | Duration: 2–6 hours | Repeat: q4–6h PRN

Na⁺ content: 4,004 mEq/L (30 mL = ~120 mEq Na⁺)

Use: Reserved for acute herniation or refractory ICP elevation unresponsive to 3% NaCl or mannitol.

⚠ Contraindications & Cautions:
• MUST use central venous catheter — peripheral administration causes severe phlebitis and tissue necrosis
• Serum Na⁺ ≥160 mEq/L
• Decompensated CHF / Pulmonary edema
• Rapid administration (<10 min) — risk of hypotension, bradycardia
• All contraindications of 3% NaCl also apply
✅ Monitoring:
• Same as 3% NaCl + central line patency check
• Serum Na⁺ q2–4h after each dose (expect larger Na⁺ shifts)
• Continuous cardiac monitoring during infusion
Glycerol 10% — 0.5–1 g/kg IV over 30–60 min (or PO in non-emergent)

Onset: 30–60 min | Duration: 4–6 hours | Repeat: q6–8h

Route: IV (10% solution) or PO (50% solution, 1–1.5 g/kg mixed with juice)

Characteristics: Metabolized by the liver, provides caloric value (~4.3 kcal/g). Milder osmotic effect compared to mannitol/HTS. More commonly used in Asia/Europe.

⚠ Contraindications & Cautions:
• Diabetes mellitus (uncontrolled) — metabolized to glucose; can cause severe hyperglycemia
• Hepatic failure — hepatic metabolism impaired; accumulation risk
• Renal failure — reduced excretion
• Dehydration / Hypovolemia
• Hemolytic conditions — IV glycerol can cause hemolysis if administered too rapidly
• Hereditary fructose intolerance
✅ Monitoring:
• Blood glucose q2–4h (especially in diabetics)
• Serum osmolality, renal function
• Signs of hemolysis if IV route used (hemoglobinuria, LDH, haptoglobin)
Tier 2 — Second-Line Therapies
💨 Mild Hyperventilation

• Target PaCO₂ 32–35 mmHg (temporizing measure only)

• Reduces ICP by cerebral vasoconstriction → decreased cerebral blood volume

• Effect begins within seconds, peaks at 15–30 min

• Duration: Use only as a bridge — effectiveness wanes after 4–6 hours due to CSF bicarbonate compensation

⚠ Critical Warnings:
• Avoid PaCO₂ <30 mmHg — aggressive hyperventilation worsens cerebral ischemia
• Avoid within 24 hours post-injury — CBF already critically reduced in acute phase (BTF Level III)
• If used, monitor SjvO₂ (jugular venous O₂ sat, target >55%) or PbtO₂ (>20 mmHg) to detect cerebral ischemia
• Do NOT use prophylactically — only for acute ICP elevation refractory to Tier 1
📈 MAP Challenge (Autoregulation Assessment)

• Purpose: Assess static pressure autoregulation (sPAR) status to guide CPP management

• Method: Increase MAP/CPP by 10 mmHg for 20 min using fluid bolus and/or norepinephrine

• Interpretation:

 → Intact sPAR: ICP decreases (cerebral vasoconstriction) → maintain the elevated MAP/CPP

 → Impaired sPAR: ICP increases (passive vasodilation) → stop vasopressor, return MAP to baseline

✅ During MAP Challenge:
• Do NOT adjust osmotherapy, sedation, or EVD during the challenge
• Continuous ICP and MAP monitoring required
• Record baseline and post-challenge ICP values
❤ CPP Optimization

• Based on MAP Challenge result, individualize CPP target

• If sPAR intact: may benefit from higher CPP target (up to 70–80 mmHg)

• If sPAR impaired: avoid pushing CPP above 70 — may worsen ICP and cause ARDS

• Use norepinephrine as first-line vasopressor for MAP support

💪 Neuromuscular Blockade (NMB) Trial

• Consider a trial dose of NMB agent to assess ICP response

• Cisatracurium 0.1–0.2 mg/kg bolus, then 1–3 mcg/kg/min infusion (preferred — organ-independent Hofmann elimination)

• Rocuronium 0.6–1.2 mg/kg bolus, then 0.3–0.6 mg/kg/hr infusion (alternative)

• Reduces ICP by eliminating shivering, coughing, and ventilator dyssynchrony

⚠ Cautions:
• Must ensure adequate sedation/analgesia first — paralysis without sedation is inhumane and undetectable
• Obscures neurological examination — limits pupil reactivity as only clinical assessment
• Increases risk of ICU-acquired weakness with prolonged use (>48h)
• Monitor with Train-of-Four (TOF) — target 1–2/4 twitches
• Increased DVT/PE risk — ensure thromboprophylaxis
Tier 3 — Rescue Therapies HIGH RISK
💥 Barbiturate Coma

Thiopental:

• Loading: 5–10 mg/kg IV slow bolus, then repeat 5 mg/kg q10min until ICP controlled or burst-suppression on EEG

• Maintenance: 3–5 mg/kg/hr continuous infusion

Pentobarbital (alternative):

• Loading: 10 mg/kg over 30 min, then 5 mg/kg/hr × 3h

• Maintenance: 1–3 mg/kg/hr, titrate to burst-suppression

Target: EEG burst-suppression (3–10 second bursts)

⚠ Critical Contraindications & Risks:
• Hemodynamic instability / Hypotension — barbiturates cause profound myocardial depression and vasodilation; requires vasopressor support in most patients
• Immunosuppression — significantly increases infection risk (pneumonia, sepsis)
• Paralytic ileus — delays enteral nutrition
• Hepatic dysfunction — prolonged elimination
• Completely abolishes neurological exam — only ICP/PbtO₂ and pupil reactivity remain assessable
• No clear mortality benefit demonstrated (Cochrane 2012) — use only as last-resort medical therapy
✅ Monitoring:
• Continuous EEG (mandatory — titrate to burst-suppression)
• Continuous arterial BP + CVP monitoring
• Serum barbiturate levels if available
• Core temperature (barbiturates cause hypothermia)
🩸 Decompressive Craniectomy (DC)

• Surgical removal of a large bone flap (≥12 × 15 cm or bifrontal) to allow brain expansion

• DECRA trial (2011): Early bifrontal DC for diffuse TBI → reduced ICP but worse functional outcomes

• RESCUEicp trial (2016): Last-resort DC → reduced mortality (26.9% vs 48.9%) but increased proportion of survivors with severe disability

• Current recommendation: Reserve for refractory ICP elevation after maximal medical therapy has failed

⚠ Relative Contraindications:
• Bilateral fixed, dilated pupils for >4 hours — suggests irreversible brainstem damage
• GCS 3 with bilateral absent pupillary reflexes
• Devastating primary brain injury incompatible with meaningful recovery
• Coagulopathy — must correct before surgery
• Shared decision-making with family is essential regarding expected outcomes
❄ Mild Hypothermia

• Target core temperature 35–36°C (mild therapeutic hypothermia)

• Reduces cerebral metabolic rate and ICP

• Eurotherm3235 trial (2015): Hypothermia (32–35°C) for ICP management → worse outcomes at 6 months. Trial stopped early.

• Current consensus: 35–36°C may be considered as rescue; avoid ≤35°C for ICP management

⚠ Risks:
• Coagulopathy — hypothermia impairs clotting cascade
• Cardiac arrhythmias — QT prolongation, bradycardia, VF risk at <32°C
• Immunosuppression / increased infection risk
• Electrolyte shifts (hypokalemia during cooling, hyperkalemia during rewarming)
• Rebound ICP elevation during rewarming — rewarm slowly (0.25°C/hr)

Clinical Assessment Summary








    
Recent Updates

    
    
        
  • The American College of Surgeons published updated TBI Best Practices Guidelines (2024), reinforcing practical bedside targets: ICP <22 mmHg, CPP 60–70 mmHg, hemoglobin transfusion threshold ≥7 g/dL, and SBP ≥110 mmHg when ICP is not monitored.
    • 
        
  • Severe-TBI care now combines the BTF 4th-edition guidelines with the SIBICC tiered algorithms; routine brain-tissue-oxygen-directed therapy and liberal transfusion thresholds remain unproven in recent trials.
    • 
    

    
American College of Surgeons Committee on Trauma. Best Practices Guidelines: The Management of Traumatic Brain Injury (2024).

    
Key Knowledge Points

    
    
        
  • Monroe-Kellie Doctrine: The skull is a rigid box containing brain (~80%), CSF (~10%), and blood (~10%). An increase in any one component must be compensated by a decrease in another, or ICP rises.
    • 
        
  • ICP threshold for treatment: Current guidelines recommend initiating ICP-lowering therapy when ICP exceeds 20–22 mmHg. Both absolute values and trends matter — a rising trajectory is more concerning than a single measurement.
    • 
        
  • CPP target 60–70 mmHg. CPP below 60 mmHg risks cerebral ischemia; above 70 mmHg, aggressive vasopressor use increases ARDS risk. The MAP Challenge in Tier 2 can help individualize the target.
    • 
        
  • HTS vs Mannitol: Hypertonic saline has a reflection coefficient of 1.0 (no BBB penetration) vs 0.9 for mannitol, resulting in less rebound ICP. HTS also maintains hemodynamic stability. Recent guidelines favor HTS, but both remain acceptable first-line agents.
    • 
        
  • Avoid hypotonic fluids. Even a single episode of hypotension (SBP <90 mmHg) doubles mortality in TBI. Use isotonic or hypertonic crystalloids exclusively.
    • 
        
  • Hyperventilation is a bridge, not a treatment. PaCO₂ 32–35 mmHg is Tier 2 only. Below 30 mmHg causes dangerous cerebral ischemia. Efficacy wanes within hours.
    • 
        
  • Steroids have NO role in TBI. The CRASH trial (10,008 patients) demonstrated increased mortality with corticosteroids in traumatic brain injury. Do not use dexamethasone for ICP in TBI. (Exception: vasogenic edema from brain tumors — dexamethasone is first-line.)
    • 
        
  • Tiered approach is essential. The SIBICC algorithm emphasizes moving from lower-risk (Tier 1) to higher-risk (Tier 3) interventions sequentially, with inter-tier reassessment for remediable causes.
    • 
    








    
About This ICP Management Guideline

    
The Intracranial Pressure (ICP) Management Guideline is an interactive clinical decision-support tool designed to guide clinicians through a structured, tiered approach to managing elevated intracranial pressure. Intracranial hypertension is a neurological emergency that can result from traumatic brain injury, intracranial hemorrhage, ischemic stroke with malignant edema, CNS infections, hepatic encephalopathy, and brain tumors. Untreated, it leads to cerebral herniation and death. This ICP management guideline integrates the latest evidence from the Brain Trauma Foundation (BTF) 4th edition, the Seattle International Severe TBI Consensus Conference (SIBICC) algorithm, the ACS TBI 2024 best practices, and the Neurocritical Care Society (NCS) 2020 cerebral edema guidelines. It provides a comprehensive protocol spanning from baseline neuroprotective measures (Tier 0) through first-line osmotherapy with dose calculations (Tier 1), second-line interventions such as hyperventilation and MAP Challenge (Tier 2), to rescue therapies including barbiturate coma and decompressive craniectomy (Tier 3).


    
How to Use This Guideline

    
Step 1 — Enter Patient Weight: Use the digit buttons to enter the patient’s body weight in kilograms. This is used to calculate weight-based osmotherapy doses for mannitol, 3% NaCl, and glycerol.

    
Step 2 — Select Management Tier: Click on the appropriate tier based on the clinical situation. Tier 0 should be initiated for all patients with suspected or confirmed intracranial hypertension. Progress to higher tiers only when lower-tier interventions fail to control ICP.

    
Step 3 — Osmotherapy Selection (Tier 1): Click on the specific osmotherapy agent to view its dosing, contraindications, and monitoring requirements. The calculator automatically computes weight-based doses. Review all contraindications before administering any agent.

    
Step 4 — Clinical Assessment Summary: After selecting a tier and osmotherapy agent, a summary is generated that can be copied into the EMR progress note for documentation.

    
General Principle: Always address Tier 0 baseline measures first. The tiered approach is sequential — do not skip to higher tiers without exhausting lower tiers, and reassess the patient for remediable causes when advancing between tiers.


    
Clinical Interpretation & Limitations

    
This ICP management guideline is based on the SIBICC consensus algorithm (class III evidence), the BTF 4th edition guidelines, and the most recent published reviews and meta-analyses through 2025. The tiered framework reflects combined expert opinion from 42 internationally recognized TBI specialists and should be used as a guide, not a rigid protocol.

    
Key limitations:

    
    
        
  • The SIBICC algorithm was designed primarily for severe TBI with ICP monitors in place. Adaptation to other etiologies (stroke, hepatic failure, CNS infection) requires additional clinical judgment.
    • 
        
  • Optimal osmotherapy agent (mannitol vs HTS) remains debated. Most meta-analyses show comparable efficacy at equimolar doses, with HTS potentially preferred in hypovolemic patients.
    • 
        
  • Individual patient factors (age, comorbidities, injury severity, autoregulation status) must always guide decision-making beyond algorithmic recommendations.
    • 
        
  • Barbiturate coma and decompressive craniectomy have no proven mortality benefit with good functional outcomes — the decision to pursue Tier 3 therapies requires careful shared decision-making with patients’ families.
    • 
        
  • This tool does not replace ICP monitoring. Clinical signs of herniation (pupil dilation, posturing, Cushing response) should prompt immediate treatment regardless of tier positioning.
    • 
    


    
Frequently Asked Questions (FAQ)


    
Q1. When should ICP-lowering treatment be initiated?

    
Current guidelines recommend initiating treatment when intracranial pressure exceeds 20–22 mmHg. The BTF 4th edition uses a threshold of 22 mmHg, while the SIBICC algorithm uses 20 mmHg. In practice, a combination of ICP values, ICP waveform morphology, clinical examination (pupil changes, motor deterioration), and brain CT findings should guide the decision to treat. Treatment should not be delayed in patients showing clinical signs of herniation, even if a specific ICP value has not been measured.


    
Q2. Should I use mannitol or hypertonic saline for elevated ICP?

    
Both are effective first-line osmotherapy agents with comparable ICP-lowering efficacy at equimolar doses. Hypertonic saline has theoretical advantages: a higher osmotic reflection coefficient (1.0 vs 0.9), no diuretic effect (preserving hemodynamic stability and CPP), and lower risk of rebound ICP elevation. Recent guidelines from the NCS (2020) and ACS TBI (2024) favor hypertonic saline, particularly in hypovolemic patients. However, mannitol remains a reasonable choice and may be preferred as a bridge to emergent neurosurgery. In practice, many centers use both agents, switching to the alternative when one becomes less effective.


    
Q3. What is the target CPP in patients with elevated ICP?

    
The recommended cerebral perfusion pressure (CPP) target is 60–70 mmHg (BTF Level IIB). CPP values below 60 mmHg risk cerebral ischemia, while aggressively pushing CPP above 70 mmHg with fluids and vasopressors increases the risk of acute respiratory distress syndrome (ARDS) (BTF Level III). When ICP monitoring is unavailable, the ACS TBI 2024 guidelines recommend targeting a MAP above 80 mmHg to ensure adequate cerebral perfusion. The MAP Challenge technique in Tier 2 can help individualize the CPP target based on autoregulation status.


    
Q4. Why is prolonged hyperventilation harmful in brain injury?

    
Hyperventilation reduces intracranial pressure by causing cerebral vasoconstriction, which decreases cerebral blood volume. However, this same vasoconstriction also reduces cerebral blood flow, potentially worsening cerebral ischemia — particularly in the first 24 hours after injury when CBF is already critically reduced. Furthermore, the ICP-lowering effect of hyperventilation is only temporary (4–6 hours) because the brain’s CSF bicarbonate system compensates for the respiratory alkalosis. For these reasons, hyperventilation should only be used as a temporizing measure in Tier 2, targeting PaCO₂ of 32–35 mmHg, with monitoring of brain oxygenation (SjvO₂ or PbtO₂).


    
Q5. What are the indications for decompressive craniectomy?

    
Decompressive craniectomy is a Tier 3 rescue therapy reserved for refractory intracranial hypertension that has failed maximal medical management including Tier 1 and Tier 2 therapies. The RESCUEicp trial (2016) demonstrated that last-resort decompressive craniectomy reduces mortality compared to medical management alone (26.9% vs 48.9% at 6 months), but increases the proportion of survivors with severe disability. The DECRA trial (2011) showed that early bifrontal craniectomy for diffuse TBI reduced ICP but was associated with worse functional outcomes. Current consensus is that DC should be considered only after thoughtful shared decision-making with the family, weighing survival against quality of life.


    
Related Calculators

    

    

        
📖 Sources:

        
    
            
  1. Carney N, et al. (2017). Guidelines for the Management of Severe Traumatic Brain Injury, Fourth Edition. Neurosurgery, 80(1):6–15.
    2. 
            
  2. Hawryluk GWJ, et al. (2019). A management algorithm for patients with intracranial pressure monitoring: the SIBICC. Intensive Care Med, 45:1783–1794.
    3. 
            
  3. Chesnut R, et al. (2020). A management algorithm for adult patients with both brain oxygen and intracranial pressure monitoring: the SIBICC. Intensive Care Med, 46(5):919–929. PMID: 31965267.
    4. 
            
  4. Cook AM, et al. (2020). Guidelines for the Acute Treatment of Cerebral Edema in Neurocritical Care Patients. Neurocrit Care, 32:647–666.
    5. 
            
  5. American College of Surgeons. (2024). Best Practices Guidelines: Management of Traumatic Brain Injury.
    6. 
            
  6. Viarasilpa T. (2024). Managing Intracranial Pressure Crisis. Curr Neurol Neurosci Rep, 25:12. PMID: 39699775.
    7. 
            
  7. Bianchini L, et al. (2025). Management of intracranial hypertension with and without invasive ICP monitoring. World J Crit Care Med, 14(3):105645. PMID: 40880574.
    8. 
            
  8. Rapp A, Kobeissi H, Fahim DK. (2025). Updated Review of the Management of and Guidelines for Traumatic Brain Injury. Journal of Clinical Medicine, 14(19):6796. PMID: 41095876.
    9. 
        

    


    

        
⚠️ Disclaimer:

        
This tool is for informational and educational purposes only and is not a substitute for professional clinical judgment. All treatment decisions must be made by a qualified healthcare professional considering the individual patient’s full clinical context. Intracranial pressure management requires real-time monitoring and individualized decision-making that no algorithm can fully replace.

    






    DosePilot Logo
    
Powered by DosePilot.com











			


				





	

					

				
Nutrition Support Guide for Hospitalized Patients
			

			

						
						
							Nutrition support guide calculator in action
						
					

			

				












    

        
🍽️ Nutrition Support Guide for Hospitalized Patients

        
Evidence-based calorie, protein, and EN/PN recommendations with ASPEN & ESPEN guidelines

        
Reviewed by the DosePilot Medical Team · Last medically reviewed: June 2026

    


    
    
Patient Assessment


    

        
        

            
            
        

    


    

        
        
—

        

            

            

        

    


    

        
        

            
            
        

    


    

        
        
—

        

            

            

            

        

    


    

        
        
—

        

            

            

            

        

    


    
    

        

            

                
BMI

                
—

                
kg/m²

                

            

            

                
IBW

                
—

                
kg

            

            
            

                
Weight for Calc

                
—

                
kg

                

            

        

    


    

    
    
Clinical Conditions (select all that apply)


    

        

            
            
Mechanical Ventilation
Overfeeding caution, indirect calorimetry recommended

        

        

            
            
Sepsis / Septic Shock
Trophic feeding in acute phase → advance in recovery

        

        

            
            
CKD (Non-Dialysis)
Protein 0.55–0.8 g/kg/day (KDOQI)

        

        

            
            
CKD (Hemodialysis)
Protein 1.0–1.2 g/kg/day

        

        

            
            
CKD (CRRT)
Protein 1.5–2.5 g/kg/day

        

        

            
            
Hepatic Insufficiency
No protein restriction needed (ESPEN)

        

        

            
            
Hepatic Encephalopathy
BCAA-enriched, no protein restriction

        

        

            
            
Acute Pancreatitis
EN preferred (NJ route), fat restriction not required

        

        

            
            
Burns (>20% TBSA)
High calorie, protein 1.5–2.0 g/kg/day

        

        

            
            
Trauma / Major Surgery
High protein 1.5–2.0 g/kg/day

        

        

            
            
Obesity (BMI ≥ 30)
Hypocaloric high-protein feeding

        

        

            
            
Diabetes / Hyperglycemia
Diabetes-specific EN, enhanced glucose monitoring

        

        

            
            
Heart Failure
Fluid restriction → high-density (1.5–2.0 kcal/mL) EN

        

        

            
            
Pressure Injury
Protein 1.25–1.5, Zinc + Vitamin C supplementation

        

    


    

    
    
Nutritional Risk Screening

    


        
        

            
mNUTRIC Score — for ICU patients (score 0–9)


            

                
                

                    
                    
                    
                

            


            

                
                

                    
                    Calculate APACHE II →
                

                
Scoring: <15 (0), 15–19 (1), 20–27 (2), ≥28 (3)

            


            

                
                

                    
                    Calculate SOFA →
                

                
Scoring: <6 (0), 6–9 (1), ≥10 (2)

            


            

                
                

                    
                    
                

            


            

                
                

                    
                    
                

            


            
        


        
        

            
NRS-2002 — for General Ward patients (score 0–7)


            

                
                

                    
                    
                    
                    
                

                
0: Normal | 1: 5% loss in 3mo or intake 50–75% | 2: 5% loss in 2mo or BMI 18.5–20.5 + impaired | 3: 5% loss in 1mo or BMI <18.5 + impaired

            


            

                
                

                    
                    
                    
                    
                

                
0: Normal | 1: Chronic disease, hip fracture, DM | 2: Major abdominal surgery, stroke, severe pneumonia | 3: ICU, APACHE ≥10

            


            

                
                

                    
                    
                

            


            
        

    


    


    
    
Refeeding Syndrome Risk Assessment


    

    

        

            
            
≥10 days little or no nutritional intake

        

        

            
            
>10% unintentional weight loss in 3–6 months

        

        

            
            
Alcohol abuse or chronic diuretic / insulin / antineoplastic use

        

    


    

    


    
    
Nutrition Route & Delivery


    

        
        

            
            
            
            
            
        

    


    

    

        
        

            
            
            
        

        
    


    

        
        

            
            
            
        

        
    


    

        
        

            
            
        


        
        

            
            
            
            
        

        
    


    

    
    

    

        
Nutrition Support Recommendation

        

            
Enter patient demographics above to see recommendations.

        

    


    
    

    
    

        
🔑 Key Knowledge

        
    
            
  • Nutritional risk screening should be performed within 24–48 hours of hospital admission using validated tools (mNUTRIC for ICU, NRS-2002 for general ward).
    • 
            
  • For most non-obese hospitalized patients the target is 25–30 kcal/kg/day, but in the acute phase of critical illness conservative feeding (12–25 kcal/kg/day, or ≤70% of measured energy expenditure) is now preferred, advancing toward full targets after ~day 3. Obese patients (BMI ≥ 30) benefit from hypocaloric high-protein feeding.
    • 
            
  • Enteral nutrition (EN) is preferred over parenteral nutrition (PN) whenever the GI tract is functional — “If the gut works, use it.”
    • 
            
  • Refeeding syndrome is a potentially fatal condition; high-risk patients should start at 5–10 kcal/kg/day with aggressive electrolyte monitoring (phosphate, magnesium, potassium).
    • 
            
  • Protein targets vary by clinical condition: CKD non-dialysis 0.55–0.8 g/kg, hemodialysis 1.0–1.2 g/kg, general critically ill 1.2–1.3 g/kg, CRRT 1.5–2.5 g/kg, and burns/trauma 1.5–2.0 g/kg. Recent RCTs (EFFORT 2023, PRECISe 2024) found no benefit — and possible harm in acute kidney injury — from high protein (≥2 g/kg), so routine high-dose protein is no longer recommended.
    • 
            
  • Adjusted body weight [IBW + 0.25 × (ABW − IBW)] should be used for calorie and protein calculations in obese patients (BMI ≥ 30).
    • 
        

    


    
    

        
Recent Updates

        
    
            
  • Protein — high-dose strategy retired (2023–2024): EFFORT Protein (2023) and PRECISe (2024) found that high protein (≥2 g/kg/day) does not improve survival or recovery and may worsen outcomes — including a mortality signal in acute kidney injury not on dialysis. ESPEN 2023 now targets ~1.3 g/kg/day and discourages higher doses.
    • 
            
  • Permissive underfeeding in acute shock (NUTRIREA-3, 2023): early low-calorie/low-protein feeding caused fewer GI complications with no survival penalty, supporting conservative feeding in the first days of critical illness.
    • 
            
  • Guidelines: the ASPEN 2022 focused update and ESPEN 2023 revision both endorse conservative early energy (12–25 kcal/kg/day, or ≤70% of measured expenditure acutely), early enteral nutrition, and delayed supplemental parenteral nutrition.
    • 
        

        
Reignier J, et al. Lancet Respir Med. 2023;11(7):602–612 · Heyland DK, et al. Lancet. 2023;401:568–576 · Bels JLM, et al. Lancet. 2024;404:659–669 · Compher C, et al. JPEN. 2022;46(1):12–41 · Singer P, et al. Clin Nutr. 2023;42(9):1671–1689.


        
About This Nutrition Support Guide

        
This nutrition support guide integrates evidence from the ASPEN critical care guidelines (2016, focused update 2022) and the ESPEN ICU guideline (2019, revised 2023), together with major 2023–2025 randomized trials, to provide a comprehensive decision-support tool for hospitalized patients. It combines nutritional risk screening, calorie and protein target calculation, route selection (EN vs PN), product matching, refeeding risk assessment, and micronutrient recommendations into a single streamlined workflow for clinicians, dietitians, and nutrition support teams.

        
The guide covers both ICU and general ward patients, automatically adjusting screening tools (mNUTRIC for ICU, NRS-2002 for ward), calorie ranges, and monitoring protocols based on the clinical setting. It is designed as a clinical decision-support tool and all recommendations should be individualized based on each patient’s full clinical context.


        
How to Use This Guide

        
Step 1: Enter the patient’s clinical setting (ICU or General Ward), age, sex, height, and actual body weight. The guide automatically calculates BMI, Ideal Body Weight (IBW), and Adjusted Body Weight for obese patients.

        
Step 2: Select all applicable clinical conditions from the checklist. These conditions directly influence protein targets, formula selection, and monitoring recommendations.

        
Step 3: Complete the nutritional risk screening (mNUTRIC for ICU, NRS-2002 for General Ward) and refeeding risk assessment.

        
Step 4: Select the nutrition route (EN, PN, or EN+PN). The guide provides automatic recommendations based on the clinical scenario but allows manual override.

        
Step 5: Click “Calculate” to generate a complete nutrition support plan including calorie/protein targets (ASPEN & ESPEN), EN/PN product recommendations, micronutrient needs, and monitoring checklists.


        
Clinical Interpretation & Limitations

        
This guide provides evidence-based ranges rather than single-point recommendations. The dual display of ASPEN and ESPEN targets reflects the reality that different institutions may follow different guidelines, and clinical teams should select the most appropriate targets for their patient population and practice setting.

        
Recent evidence (2023–2025): Several large randomized trials have refined nutrition practice. NUTRIREA-3 (2023) found that early conservative (low-calorie, low-protein) feeding in shock caused fewer GI complications with no survival penalty, supporting permissive underfeeding in the acute phase. EFFORT Protein (2023) and PRECISe (2024) showed that high protein delivery (≥2 g/kg/day) does not improve outcomes and may worsen recovery — with a specific harm signal in acute kidney injury not on dialysis. ESPEN 2023 targets ~1.3 g/kg/day (ASPEN’s text still permits up to 2.0 but its 2022 update found no benefit to higher protein), so a conservative default with early enteral nutrition, advanced gradually, is now favored; condition-specific higher targets (e.g., burns, major trauma, CRRT) still apply.

        
Key limitations include: (1) Calorie and protein targets are estimates — indirect calorimetry remains the gold standard for measuring energy expenditure in critically ill patients. (2) EN and PN product databases contain estimated compositions that should be verified against local formulary and manufacturer package inserts. (3) The guide does not replace clinical judgment regarding timing of nutrition initiation, tolerance assessment, or individualized adjustments.


        
Frequently Asked Questions (FAQ)

        
Q: How do I determine calorie targets for hospitalized patients?

        
Calorie targets depend on BMI, clinical phase, and guideline preference. The ASPEN 2022 update found no outcome benefit from reaching full calories early and supports 12–25 kcal/kg/day during the first week of critical illness; ESPEN advises ≤70% of measured energy expenditure in the acute phase, advancing to 80–100% of measured expenditure after ~day 3, with full weight-based targets (~25–30 kcal/kg/day) in the recovery phase. Indirect calorimetry remains the gold standard when available. For obese patients (BMI ≥ 30), hypocaloric high-protein feeding is recommended.

        
Q: Has the high-protein recommendation changed?

        
Yes. Older guidance suggested up to 2.0 g/kg/day or more for critically ill patients. Randomized trials published in 2023–2024 (EFFORT Protein, PRECISe) found that higher protein does not improve survival or recovery and may cause harm — particularly slower recovery and higher mortality in acute kidney injury not on dialysis. ESPEN 2023 targets ~1.3 g/kg/day and discourages higher doses (ASPEN still permits up to 2.0 but found no benefit), so a conservative default is now favored for most critically ill patients, with higher amounts reserved for specific conditions (e.g., burns, major trauma, CRRT).

        
Q: What is the mNUTRIC score and when should it be used?

        
The modified NUTRIC (mNUTRIC) score is a validated nutritional risk screening tool for ICU patients. It incorporates age, APACHE II, SOFA score, comorbidities, and days from hospital to ICU admission. A score ≥ 5 indicates high nutritional risk requiring aggressive nutrition support.

        
Q: When should parenteral nutrition (PN) be started?

        
PN is indicated when the GI tract is non-functional or when EN alone cannot meet nutritional targets. Per ASPEN, if EN is not feasible, PN should be considered within 7 days for low-risk patients and started early (low-dose, avoiding overfeeding) in high-nutritional-risk or malnourished patients. Early supplemental PN added to EN should be delayed (EPaNIC, 2011).

        
Q: How is refeeding syndrome risk assessed?

        
Refeeding risk is assessed by BMI (below 16 indicates extreme risk), duration of fasting (10+ days), recent unintentional weight loss (10%+ in 3–6 months), and history of alcohol abuse or chronic diuretic use. High-risk patients should start nutrition at reduced calorie levels (5–10 kcal/kg/day) with aggressive electrolyte monitoring.

        
Q: What is the difference between ASPEN and ESPEN calorie recommendations?

        
Both guidelines now converge on conservative early feeding. The ASPEN 2022 update supports 12–25 kcal/kg/day during the first week (no benefit from early full calories), while ESPEN 2023 advises ≤70% of measured energy expenditure acutely, advancing to 80–100% of measured expenditure after ~day 3 (full weight-based ~25–30 kcal/kg/day in the recovery phase). For obese patients, ASPEN recommends 11–14 kcal/kg actual body weight and ESPEN ~20–25 kcal/kg adjusted body weight. This guide displays both frameworks so the clinical team can choose the most appropriate target.


        
Related Calculators

        

        

            
📖 Sources:

            
    
                
  1. Compher C, et al. (2022). Guidelines for the provision of nutrition support therapy in the adult critically ill patient: SCCM/ASPEN focused update. JPEN J Parenter Enteral Nutr, 46(1):12–41. DOI:10.1002/jpen.2267
    2. 
                
  2. Singer P, et al. (2023). ESPEN practical and partially revised guideline: Clinical nutrition in the ICU. Clinical Nutrition, 42(9):1671–1689. DOI:10.1016/j.clnu.2023.07.011
    3. 
                
  3. Reignier J, et al. (2023). Early nutrition in critically ill patients (NUTRIREA-3): a randomised controlled trial. Lancet Respir Med, 11(7):602–612.
    4. 
                
  4. Heyland DK, et al. (2023). The EFFORT Protein trial: high vs usual protein in critically ill patients. Lancet, 401(10376):568–576.
    5. 
                
  5. Bels JLM, et al. (2024). High vs standard enteral protein in critically ill patients (PRECISe): a randomised, double-blind trial. Lancet, 404(10454):659–669.
    6. 
                
  6. McClave SA, et al. (2016). Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: SCCM and ASPEN. JPEN J Parenter Enteral Nutr.
    7. 
                
  7. Singer P, et al. (2019). ESPEN guideline on clinical nutrition in the intensive care unit. Clinical Nutrition.
    8. 
                
  8. Kondrup J, et al. (2003). Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. Clinical Nutrition.
    9. 
                
  9. Heyland DK, et al. (2011). A novel nutritional adequacy tool for critically ill patients (NUTRIC score). Critical Care.
    10. 
                
  10. NICE (2006, updated 2017). Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition. Clinical guideline CG32.
    11. 
                
  11. Friedli N, et al. (2018). Management and prevention of refeeding syndrome in medical inpatients: An evidence-based and consensus-supported algorithm. Nutrition.
    12. 
            

        


        

            
⚠️ Disclaimer:

            
This tool is for informational and educational purposes only and is not a substitute for professional clinical judgment. All treatment decisions must be made by a qualified healthcare professional considering the individual patient’s full clinical context. EN and PN product compositions are estimates and must be verified against manufacturer package inserts before clinical use.

        

    


    

        DosePilot Logo
        
Powered by DosePilot.com

    











			


				





	

					

				
Thrombocytopenia Diagnostic Algorithm
			

			

						
						
							thrombocytopenia diagnostic algorithm calculator in action
						
					

			

				














    
🧠 Thrombocytopenia Diagnostic Algorithm

    
A Step-by-Step Approach to Low Platelets in Hospitalized Patients

    
Reviewed by the DosePilot Medical Team · Last medically reviewed: June 2026







    

        Step 1
        Peripheral Blood Smear Review
        
First, confirm true thrombocytopenia. Rule out pseudothrombocytopenia (EDTA-induced platelet clumping).

    

    

        
        
        
    







    

        Step 2
        Severity Classification
        
Classify the degree of thrombocytopenia. Severity influences differential diagnosis and transfusion decisions.

    

    

        
        
        
    







    

        Step 3
        Clinical Context
        
Select ALL that apply. Multiple causes are common — 37% of hospitalized patients have ≥3 concurrent etiologies.

    

    

        
        
        
        
        
        
        
        
    







    

        Step 4
        Key Laboratory Findings
        
Select all abnormal findings. The lab pattern differentiates DIC, TMA, HIT, and other etiologies.

    

    

        
Coagulation

        
        
        
        
Hemolysis

        
        
        
        
Organ Function

        
        
    

    

        
    










    
📋 Differential Diagnosis & Recommended Workup

    

    

    

    
🧪 Recommended Workup

    

    

        
    







    

        
Clinical Assessment Summary

        
    

    







    
Recent Updates

    
    
        
  • The 2025 AABB/ICTMG platelet transfusion guideline reaffirms restrictive thresholds: prophylactic transfusion at <10,000/μL, <50,000/μL before major surgery, and platelets are relatively contraindicated in TTP and HIT unless the patient is bleeding.
    • 
        
  • PLOT-ICU, the largest international ICU cohort, found thrombocytopenia in 43% of ICU patients, with septic shock raising the odds of severe thrombocytopenia roughly 6.9-fold.
    • 
        
  • The 2025 ISTH focused update now favors recombinant ADAMTS13 over plasma in congenital TTP; immune-TTP therapy (plasma exchange, steroids, caplacizumab, rituximab) is unchanged.
    • 
    

    
Metcalf RA, et al. Platelet Transfusion: 2025 AABB and ICTMG International Clinical Practice Guidelines. JAMA. 2025;334(7):606–617. PMID 40440268

    
Key Knowledge Points

    
    
        
  • Prevalence: Thrombocytopenia affects 25–55% of hospitalized patients, especially in critical care settings. The PLOT-ICU study reported an incidence of 43% in the ICU population.
    • 
        
  • Always check the smear first. Pseudothrombocytopenia from EDTA-induced platelet clumping is a common artifact. Redraw in a citrate tube to confirm.
    • 
        
  • Sepsis is the #1 cause, responsible for nearly half of hospital-acquired thrombocytopenia. Septic shock increases the risk ~6.9-fold.
    • 
        
  • HIT: Think thrombosis, not bleeding. Despite the name, HIT’s primary danger is arterial and venous thrombosis. Stop ALL heparin (including flushes) and start an alternative anticoagulant if 4T score ≥4.
    • 
        
  • TTP is rare but deadly. Untreated mortality exceeds 90%. If schistocytes + thrombocytopenia + normal coagulation → suspect TMA. Do NOT transfuse platelets. Initiate plasma exchange.
    • 
        
  • Multiple causes are common. 37% of hospitalized patients with thrombocytopenia have ≥3 simultaneous etiologies. Think broadly.
    • 
        
  • Platelet trend matters. A >50% drop from baseline may be more significant than the absolute count. Failure to recover by day 14 is associated with mortality rates up to 66%.
    • 
        
  • Transfusion threshold: Prophylactic transfusion at <10,000/μL (non-bleeding); <50,000/μL (pre-procedure); contraindicated in TTP/HIT.
    • 
    








    
About This Diagnostic Algorithm

    
The Thrombocytopenia Diagnostic Algorithm is an interactive clinical decision-support tool designed to guide clinicians through a structured evaluation of low platelet counts in hospitalized patients. Thrombocytopenia is rarely caused by a single etiology — studies show that 37% of affected patients have three or more concurrent causes. This tool walks clinicians through four systematic steps: confirming true thrombocytopenia via peripheral blood smear, classifying severity, assessing clinical context, and evaluating laboratory findings. The algorithm then generates a prioritized differential diagnosis with recommended workup and key safety alerts.


    
How to Use This Algorithm

    
Step 1 — Peripheral Blood Smear: Before investigating causes, confirm the platelet count is truly low. EDTA-induced platelet clumping (pseudothrombocytopenia) is a common artifact that can be identified on the smear. If clumping is present, redraw blood in a citrate tube.

    
Step 2 — Severity: Classify thrombocytopenia as mild (100–150K), moderate (50–100K), or severe (<50K). Severity helps prioritize the differential and determine transfusion needs.

    
Step 3 — Clinical Context: Select all applicable clinical scenarios. Multiple selections are encouraged — thrombocytopenia in hospitalized patients is often multifactorial.

    
Step 4 — Lab Findings: Check off abnormal laboratory results. The pattern of coagulation and hemolysis markers helps differentiate DIC from TMA from HIT.

    
After completing all steps, click “Analyze & Generate Differential” to receive a prioritized list of diagnoses, recommended workup, and critical safety alerts. The Calculation Summary can be copied directly into your EMR progress note.


    
Clinical Interpretation & Limitations

    
This algorithm is based on current evidence from ISTH, ASH guidelines, and expert consensus from critical care literature (2018–2025). However, clinical medicine requires nuanced judgment that no algorithm can fully replace.

    
Key limitations:

    
    
        
  • This tool provides a structured framework, not a definitive diagnosis. All results require clinical correlation.
    • 
        
  • Rare causes (e.g., post-transfusion purpura, thrombotic storm, hemophagocytic lymphohistiocytosis) are not included in the primary algorithm.
    • 
        
  • The 4T score for HIT should be formally calculated separately for accurate risk stratification — this algorithm provides a screening prompt, not a substitute.
    • 
        
  • ADAMTS13 activity testing is not available at all institutions. The PLASMIC score can be used as an alternative predictor of TTP probability.
    • 
        
  • In pregnancy, additional diagnoses (HELLP, preeclampsia, acute fatty liver of pregnancy) must be considered.
    • 
    


    
Frequently Asked Questions (FAQ)


    
Q1. What is the most common cause of thrombocytopenia in hospitalized patients?

    
Sepsis is the leading cause, accounting for nearly half of hospital-acquired thrombocytopenia. The 2025 Annals of Intensive Care review confirmed this finding. Septic shock specifically increases the risk of severe thrombocytopenia by approximately 6.9-fold (PLOT-ICU study). The mechanism is multifactorial: endothelial damage, splenic sequestration, bone marrow suppression, and consumptive coagulopathy all contribute.


    
Q2. When should I suspect HIT (Heparin-Induced Thrombocytopenia)?

    
Suspect HIT when the platelet count drops more than 50% from baseline, typically 5–10 days after heparin initiation. Use the 4T scoring system to assess pre-test probability. A low score (0–3) has a negative predictive value of 99.8%, effectively ruling out HIT. For intermediate (4–5) or high (6–8) scores, discontinue ALL heparin immediately and start an alternative anticoagulant such as argatroban or bivalirudin.


    
Q3. Why is platelet transfusion contraindicated in TTP?

    
In TTP (Thrombotic Thrombocytopenic Purpura), autoantibodies against ADAMTS13 cause uncontrolled platelet activation and microvascular thrombosis. Transfused platelets are consumed by this pathological process, paradoxically worsening organ damage by providing more substrate for microthrombi. The treatment of choice is plasma exchange, which removes the pathogenic antibodies and replenishes functional ADAMTS13.


    
Q4. How do I differentiate DIC from TMA at the bedside?

    
Both DIC and TMA can present with thrombocytopenia and schistocytes on the peripheral smear. The key differentiator is the coagulation profile: DIC shows prolonged PT/aPTT, elevated D-dimer, and low fibrinogen (consumptive coagulopathy), whereas TMA typically has normal coagulation studies with predominant hemolysis markers (markedly elevated LDH, very low haptoglobin, indirect hyperbilirubinemia). A negative direct Coombs test supports TMA over autoimmune hemolytic anemia.


    
Q5. What is pseudothrombocytopenia and how common is it?

    
Pseudothrombocytopenia is a laboratory artifact where EDTA anticoagulant in the collection tube causes platelets to clump together. The automated analyzer counts these clumps as single large particles, resulting in a falsely low platelet count. It occurs in approximately 0.1% of the general population but is an essential first-step rule-out in hospitalized patients because it prevents unnecessary workup. Confirmation requires a peripheral blood smear showing platelet clumps and/or re-collection in a citrate tube.


    
Related Calculators

    

    

        
📖 Sources:

        
    
            
  1. Pène F, Russell L, Aubron C. (2025). Thrombocytopenia in the intensive care unit: diagnosis and management. Annals of Intensive Care, 15(1):25. PMID: 39985745.
    2. 
            
  2. Vincent JL, et al. (2018). Thrombocytopenia in the ICU: disseminated intravascular coagulation and thrombotic microangiopathies — what intensivists need to know. Critical Care, 22:158. PMID: 29895296.
    3. 
            
  3. Anthon CT, et al. (2023). Thrombocytopenia and platelet transfusions in ICU patients: an international inception cohort study (PLOT-ICU). Intensive Care Medicine, 49(11):1327–1338. PMID: 37812225.
    4. 
            
  4. Metcalf RA, et al. (2025). Platelet Transfusion: 2025 AABB and ICTMG International Clinical Practice Guidelines. JAMA, 334(7):606–617. PMID: 40440268.
    5. 
            
  5. Zheng XL, et al. (2025). 2025 focused update of the 2020 ISTH guidelines for the management of thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis. PMID: 40533296.
    6. 
            
  6. Heparin-Induced Thrombocytopenia. (2023). StatPearls. NCBI Bookshelf NBK482330.
    7. 
            
  7. Thrombocytopenia. (2025). StatPearls. NCBI Bookshelf NBK542208.
    8. 
            
  8. Walter JM. (2020). Thrombocytopenia in the Intensive Care Unit. Evidence-Based Critical Care. Springer.
    9. 
            
  9. Farkas J. (2024). Thrombocytopenia. Internet Book of Critical Care (IBCC). EMCrit Project.
    10. 
        

    


    

        
⚠️ Disclaimer:

        
This tool is for informational and educational purposes only and is not a substitute for professional clinical judgment. All treatment decisions must be made by a qualified healthcare professional considering the individual patient’s full clinical context.

    






    DosePilot Logo
    
Powered by DosePilot.com










			


				





	

					

				
AFib with RVR Treatment Guideline
			

			

						
						
							The DosePilot Interactive AFib with RVR Treatment Guideline tool in action, showing the clinical pathway.
						
					

			

				









    

        

            
⚡️ Interactive AFib with RVR Treatment Guideline

            
Navigate the Clinical Pathway for Stable & Unstable Patients

            
Reviewed by the DosePilot Medical Team · Last medically reviewed: June 2026

        


        

            
            

                
                
            

        


        

            
            

                
                
            

        


        


        

            
Recommended Treatment Protocol

            

        


        

             

                
                
After acute rate control, all patients with AFib require stroke risk stratification to guide anticoagulation therapy.

                Go to CHA₂DS₂-VASc Score Calculator
            

        

    


    

        
Recent Updates

        
    
            
  • IV non-dihydropyridine calcium channel blockers (diltiazem, verapamil) are now Class 3: Harm in AFib with RVR and moderate-to-severe LV systolic dysfunction (HFrEF), with or without decompensated heart failure — a broadening from the prior decompensated-only caution.
    • 
            
  • Digoxin is a guideline second-line agent (alone or combined with a beta-blocker/CCB) when first-line agents are ineffective or contraindicated, and is favored in HFrEF or hypotension; IV magnesium is a reasonable adjunct for rate control.
    • 
            
  • A lenient initial rate target (resting HR <110 bpm) is acceptable unless the patient remains symptomatic or is developing tachycardia-mediated cardiomyopathy.
    • 
            
  • The 2024 ESC guideline introduced the AF-CARE framework and replaced CHA₂DS₂-VASc with CHA₂DS₂-VA (sex category dropped from routine scoring), and tightened the early-cardioversion window from 48h to 24h of AF duration.
    • 
        

        
Source: Joglar JA, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation. Circulation 2024;149(1):e1–e156. PMID: 38033089. See also Van Gelder IC, et al. 2024 ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2024;45(36):3314–3414. PMID: 39210723.

        
Key Knowledge Points

        
    
            
  • The first step in any AFib with RVR treatment guideline is to assess hemodynamic stability. Unstable patients require immediate synchronized electrical cardioversion. If hypotension is driven by the tachyarrhythmia itself, treat as unstable rather than reaching for rate-slowing drugs.
    • 
            
  • In stable patients, the goal is rate control (a lenient resting target of <110 bpm is acceptable). The choice of agent depends on LVEF and comorbidities such as hypotension or severe asthma.
    • 
            
  • Beta-blockers and non-dihydropyridine calcium channel blockers are first-line when LVEF >40%. IV non-DHP CCBs are Class 3: Harm in moderate-to-severe LV dysfunction (HFrEF).
    • 
            
  • Digoxin (second-line) and amiodarone are options for HFrEF; IV magnesium is a reasonable adjunct. Note amiodarone may chemically convert AF — weigh anticoagulation status, and it raises digoxin/warfarin/DOAC levels.
    • 
            
  • CRITICAL: In suspected pre-excitation (e.g., WPW), AV-nodal blocking agents — beta-blockers, calcium channel blockers, digoxin, and also adenosine and IV amiodarone — are contraindicated and can provoke VF. Use procainamide or electrical cardioversion.
    • 
            
  • Before reflexively rate-controlling, look for a secondary driver (sepsis, PE, hypovolemia, thyrotoxicosis, pain, anemia, withdrawal); new-onset AFib with RVR is often a symptom. Cardioversion of AF ≥48h (ESC: >24h) or unknown duration requires ≥3 weeks of anticoagulation or a TEE unless the patient is unstable.
    • 
        

    


    

        
About This AFib with RVR Treatment Guideline

        
This interactive tool provides a streamlined clinical pathway for the acute management of atrial fibrillation with a rapid ventricular response (AFib with RVR). It is designed for healthcare professionals to quickly generate guideline-concordant treatment recommendations based on two critical decision points: patient stability and left ventricular function. This AFib with RVR treatment guideline navigator helps ensure that the chosen therapy is both safe and effective for the individual patient's clinical scenario.


        
The Treatment Pathway Explained

        
The management algorithm within this AFib with RVR treatment guideline is a branching pathway that prioritizes patient safety and hemodynamic stability.

        
    
            
  1. Assess Stability: The first and most important step. An unstable patient (defined by hypotension, altered mental status, signs of shock, ischemic chest pain, or acute heart failure) requires immediate intervention.
    2. 
            
  2. Unstable Pathway: The treatment is urgent synchronized electrical cardioversion to rapidly restore a safe heart rate and rhythm.
    3. 
            
  3. Stable Pathway: If the patient is stable, the goal is to control the heart rate (rate control). The choice of medication is then determined by the patient's cardiac function and other clinical factors.
                
      
                    
    • If LVEF > 40% (Preserved EF): IV beta-blockers (e.g., metoprolol) or non-dihydropyridine calcium channel blockers (e.g., diltiazem) are the preferred first-line agents.
      • 
                    
    • If LVEF ≤ 40% (HFrEF): Calcium channel blockers are contraindicated. IV beta-blockers may be used cautiously, but IV Digoxin or IV Amiodarone are often safer choices.
      • 
                
    
            
    4. 
        


        
Key Medication Dosing

        
    
            
  • Diltiazem: Bolus 0.25 mg/kg IV over 2 min; may re-bolus 0.35 mg/kg after 15 min, then 5–15 mg/hr infusion. (Class 3: Harm in moderate-to-severe LV dysfunction.)
    • 
            
  • Metoprolol (tartrate): 2.5–5 mg IV over 2 min, may repeat every 5 minutes up to 3 doses (max ~15 mg).
    • 
            
  • Amiodarone: 150 mg IV over 10 min, then maintenance infusion. May chemically convert AF — consider anticoagulation status.
    • 
            
  • Digoxin: 0.25–0.5 mg IV load, then 0.25 mg IV every 6 h up to ~1–1.5 mg in 24 h. Slow onset (hours) — not for rapid control as a sole agent; narrow therapeutic window.
    • 
            
  • IV Magnesium sulfate: a reasonable adjunct (e.g., 1–2 g IV) to standard rate-control agents.
    • 
            
  • Synchronized Cardioversion: Recommended starting energy for biphasic defibrillators is 100 to 200 Joules.
    • 
        


        
Frequently Asked Questions (FAQ)

        
1. What defines "hemodynamic instability" in AFib with RVR?

        
Instability is a clinical diagnosis indicated by signs of end-organ hypoperfusion due to the rapid heart rate. Key signs include: hypotension (e.g., SBP < 90 mmHg), acutely altered mental status, signs of shock (e.g., cool, clammy skin), ischemic chest pain, or acute pulmonary edema.


        
2. Why is LVEF the key factor for stable patients?

        
Because common rate control agents have different effects on cardiac contractility. Calcium channel blockers (like diltiazem) can weaken the heart's pumping function, which is dangerous in a patient who already has a weak heart (HFrEF). This makes LVEF a critical decision point for safe medication selection.


        
3. What if my stable patient is hypotensive or has severe asthma?

        
For a stable patient with borderline low blood pressure, beta-blockers and CCBs should be avoided or used with extreme caution. In this case, IV Digoxin or Amiodarone would be a better choice. For a patient with severe reactive airway disease, beta-blockers should be avoided; a CCB like Diltiazem is a safer option.


        
4. What is the absolute contraindication I must know?

        
If you suspect the patient has an accessory pathway (pre-excitation syndrome like WPW), do not use standard AV nodal blocking agents (CCBs, Beta-Blockers, Digoxin). Blocking the normal pathway can lead to extremely rapid conduction down the accessory pathway, potentially causing ventricular fibrillation. Procainamide or electrical cardioversion are the treatments of choice.


        
5. Does this AFib with RVR treatment guideline address anticoagulation?

        
This tool focuses on acute rate control. However, a crucial next step for any patient with AFib is to assess their stroke risk using the CHA₂DS₂-VASc score. We have included a link to this calculator as "Step 3" after you receive your acute treatment recommendation.


        
Related Calculators

        

        

            
📖 Sources:

            
    
                
  1. Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Patients With Atrial Fibrillation. Circulation. 2024;149(1):e1-e156. PMID: 38033089.
    2. 
                
  2. Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the EACTS. Eur Heart J. 2024;45(36):3314-3414. PMID: 39210723.
    3. 
                
  3. Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation (RACE II). N Engl J Med. 2010;362(15):1363-1373. PMID: 20231232.
    4. 
                
  4. Stiell IG, et al. Electrical cardioversion for atrial fibrillation and flutter in the emergency department. Ann Emerg Med. 2022;80(3):213-225. PMID: 35550791.
    5. 
            

        


        

            
⚠️ Disclaimer:

            
This tool is for informational and educational purposes only and is not a substitute for professional clinical judgment. All treatment decisions must be made by a qualified healthcare professional considering the individual patient's full clinical context. This AFib with RVR treatment guideline is an aid, not a replacement for clinical expertise.

        

    


    

        DosePilot Logo
        
Powered by DosePilot.com

    





			


				





	

					

				
Acute Coronary Syndrome Guideline
			

			

						
						
							The DosePilot Acute Coronary Syndrome (ACS) Guideline tool in action, showing the interactive clinical pathway for diagnosis and management.
						
					

			

				








    

        
❤️ ACS Guideline & Clinical Pathway

        
Interactive Diagnosis & Initial Management of Acute Coronary Syndrome

        
Reviewed by the DosePilot Medical Team · Last medically reviewed: June 2026

    


    

        
        

            
            
            
        

    


    

        

            
            

                
                
            

        

    


    


    

        
Diagnosis & Initial Management Plan

        

            

    


    

    

        
Recent Updates

        
    
            
  • Routine upstream P2Y12 pretreatment is no longer recommended in NSTE-ACS when early angiography is planned and the coronary anatomy is unknown — load at or after catheterization. Pretreatment with clopidogrel or ticagrelor may be considered only if angiography is expected to be delayed beyond 24 hours; prasugrel should not be used for pretreatment. STEMI patients are still loaded at diagnosis.
    • 
            
  • Ticagrelor or prasugrel are preferred over clopidogrel for ACS managed with PCI; default dual antiplatelet therapy (DAPT) is at least 12 months unless the patient is at high bleeding risk.
    • 
            
  • Earlier, more aggressive lipid lowering: high-intensity statin for all, with early addition of ezetimibe ± a PCSK9 inhibitor when LDL-C remains ≥70 mg/dL (recheck at 4–8 weeks).
    • 
            
  • Complete revascularization is now recommended for STEMI with multivessel disease, and radial access is the preferred default approach.
    • 
        

        
Source: Rao SV, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. Circulation 2025;151(13):e771–e862. PMID: 40014670.

        
Key Knowledge Points

        
    
            
  • This Acute Coronary Syndrome Guideline pathway helps standardize initial assessment and management based on EKG and troponin findings.
    • 
            
  • For STEMI, the immediate goal is reperfusion. “Time is muscle,” and the system goal is a first medical contact-to-device time of ≤90 minutes for PCI. Complete revascularization of significant non-culprit lesions and radial access are preferred.
    • 
            
  • For NSTE-ACS (NSTEMI/Unstable Angina), initial management involves anti-ischemic therapy, antiplatelet agents, anticoagulation, and risk stratification (e.g., using GRACE or TIMI scores) to guide timing of angiography.
    • 
            
  • Antiplatelet strategy: aspirin plus an oral P2Y12 inhibitor is the backbone — but routine P2Y12 pretreatment is not recommended in NSTE-ACS when anatomy is unknown and early angiography is planned (load at/after cath). Ticagrelor or prasugrel are preferred over clopidogrel for PCI.
    • 
            
  • Nitrates and morphine are used for symptom relief but do not improve mortality; morphine can delay the absorption and onset of oral P2Y12 inhibitors, so reserve it for refractory ischemic pain.
    • 
            
  • Oxygen should only be administered if the patient’s oxygen saturation is <90%, as hyperoxia may be harmful.
    • 
            
  • Lipid management: begin a high-intensity statin early in all ACS patients and add ezetimibe ± a PCSK9 inhibitor when LDL-C remains ≥70 mg/dL.
    • 
        

    


    

        
About This ACS Guideline Tool

        
This interactive Acute Coronary Syndrome (ACS) Guideline tool is designed for healthcare professionals to rapidly navigate the diagnostic and initial therapeutic pathway for patients presenting with suspected ACS. By inputting key initial findings—specifically from the 12-lead EKG and high-sensitivity cardiac troponin assays—the tool provides a clear diagnosis (STEMI, NSTEMI, or Unstable Angina) and outlines the immediate, evidence-based management steps recommended by major cardiology guidelines.


        
Navigating the Diagnostic Pathway

        
The diagnosis of Acute Coronary Syndrome is a time-critical process that hinges on two key initial investigations:

        
    
            
  1. 12-Lead EKG: The EKG is the most important initial diagnostic test. It rapidly identifies patients with ST-segment elevation myocardial infarction (STEMI) who require immediate reperfusion therapy. It can also suggest NSTE-ACS through findings like ST-segment depression or T-wave inversions.
    2. 
            
  2. Cardiac Troponins: High-sensitivity cardiac troponins (hs-cTn) are the preferred biomarkers for detecting myocardial necrosis. A rise and/or fall in troponin levels above the 99th percentile upper reference limit is the hallmark of an acute myocardial infarction (MI).
    3. 
        


        
Clinical Interpretation & Management Details

        
ST-Elevation Myocardial Infarction (STEMI)

        
A diagnosis of STEMI is a medical emergency. The primary goal is immediate and complete reperfusion of the occluded coronary artery.

        
    
            
  • Reperfusion: Primary Percutaneous Coronary Intervention (PCI) is the preferred strategy if it can be performed within 120 minutes of first medical contact. If not, fibrinolytic therapy should be considered.
    • 
            
  • Medical Therapy: Initial treatment includes Aspirin, a P2Y12 inhibitor (e.g., ticagrelor or prasugrel), and parenteral anticoagulation (e.g., heparin).
    • 
        

        
Non-ST-Elevation ACS (NSTEMI & Unstable Angina)

        
Patients without ST-segment elevation are initially managed with anti-ischemic and antithrombotic therapies, followed by risk stratification to determine the timing of angiography.

        
    
            
  • Antiplatelet & Anticoagulation: Aspirin plus an oral P2Y12 inhibitor and parenteral anticoagulation. In NSTE-ACS planned for an early invasive strategy with unknown anatomy, the P2Y12 inhibitor is generally loaded at or after angiography rather than empirically in the ED (routine pretreatment is not recommended; it may be considered only if angiography is delayed beyond 24 hours, and prasugrel is not used for pretreatment).
    • 
            
  • Risk Stratification: Tools like the GRACE or TIMI risk score are used. High-risk patients benefit from an early invasive strategy (angiography within 24 hours), while lower-risk patients may be managed with a more conservative approach.
    • 
        


        
Key Antithrombotic Dosing & Cautions

        
    
            
  • Aspirin: 162–325 mg non–enteric-coated, chewed, as soon as ACS is suspected.
    • 
            
  • P2Y12 inhibitor (load per timing above): ticagrelor 180 mg; prasugrel 60 mg (avoid for pretreatment; contraindicated with prior stroke/TIA; use caution or avoid if ≥75 years or <60 kg); clopidogrel 300–600 mg when potent agents are contraindicated, unavailable, or oral anticoagulation is needed.
    • 
            
  • Unfractionated heparin: ~60 units/kg IV bolus (max ≈4,000 units) followed by a 12 units/kg/hr infusion (max ≈1,000 units/hr), titrated to aPTT/anti-Xa; when a GP IIb/IIIa inhibitor is used the bolus is 50–70 units/kg. Enoxaparin is an alternative.
    • 
            
  • Cautions: morphine delays oral P2Y12 absorption (reserve for refractory pain); nitrates are contraindicated in RV infarction, severe aortic stenosis, and recent PDE5-inhibitor use (sildenafil <24h, tadalafil <48h); in cardiogenic shock, culprit-lesion-only PCI is preferred over routine immediate multivessel PCI.
    • 
        


        
Limitations

        
This tool provides initial guidance based on a simplified algorithm. It does not replace comprehensive clinical evaluation and judgment. The management of ACS is complex and must account for patient-specific factors, contraindications, and institutional resources. This Acute Coronary Syndrome guideline tool is for educational and informational purposes only.


        
Frequently Asked Questions (FAQ)

        
1. What is the difference between NSTEMI and Unstable Angina?

        
Both are types of NSTE-ACS. The key difference is the presence of myocardial necrosis. In NSTEMI, there is enough ischemia to cause myocyte death, resulting in elevated cardiac troponin levels. In Unstable Angina, the ischemia is not severe enough to cause detectable necrosis, so troponin levels remain normal.


        
2. Is the MONA protocol (Morphine, Oxygen, Nitrates, Aspirin) still recommended?

        
The “MONA” acronym is outdated as a universal protocol. Aspirin is the only component given routinely. Oxygen is only for hypoxic patients (SpO₂ < 90%). Nitrates are for active chest pain but are contraindicated in right ventricular infarction or severe aortic stenosis. Morphine is a reasonable choice for persistent ischemic chest pain not relieved by nitrates.


        
3. What is a “P2Y12 inhibitor”?

        
P2Y12 inhibitors are a class of potent antiplatelet agents that block the P2Y12 receptor on platelets, preventing their activation and aggregation. They are a cornerstone of DAPT in ACS. Examples include clopidogrel, prasugrel, and ticagrelor.


        
4. Why is a central line not required for vasopressors in ACS initially?

        
While central access is ideal for sustained vasopressor infusions, initiating pressors like norepinephrine via a well-sited, large-bore peripheral IV in a proximal vein (e.g., antecubital fossa) is acceptable in an emergency to rapidly restore perfusion while central access is being obtained. This is a crucial temporizing measure.


        
5. Can this Acute Coronary Syndrome guideline be used for patients with a left bundle branch block (LBBB)?

        
A new or presumed-new LBBB in the context of ischemic symptoms is considered a “STEMI equivalent” and should trigger immediate reperfusion protocols. This tool’s “STEMI” pathway applies in that situation.


        
Related Calculators

        

        

            
📖 Sources:

            
    
                
  1. Rao SV, O’Donoghue ML, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. Circulation. 2025;151(13):e771-e862. PMID: 40014670.
    2. 
                
  2. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720-3826. PMID: 37622654.
    3. 
                
  3. Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization. Circulation. 2022;145(3):e18-e114. PMID: 34882435.
    4. 
                
  4. Hofmann R, James SK, Jernberg T, et al. Oxygen Therapy in Suspected Acute Myocardial Infarction (DETO2X-AMI). N Engl J Med. 2017;377(13):1240-1249. PMID: 28844200.
    5. 
            

        


        

            
⚠️ Disclaimer:

            
This tool is for informational and educational purposes only and is not a substitute for professional clinical judgment. All treatment decisions must be made by a qualified healthcare professional considering the individual patient’s full clinical context.

        

    


    

        DosePilot Logo
        
Powered by DosePilot.com

    





			


				





	

					

				
DKA & HHS Treatment Guideline
			

			

						
						
							The DKA Treatment Guideline calculator in action, showing the time-based protocol for managing diabetic ketoacidosis.
						
					

			

				








  

    

      
🩸 DKA & HHS Treatment Guideline

      

        Management protocols for hyperglycemic crises.
      

      
Reviewed by the DosePilot Medical Team · Last medically reviewed: June 2026

    


    

      
      

        
        
      

    


    


    

      

        DKA Treatment Protocol
      

      

    


    

      
Recent Updates

      
    
        
  • Jun 2026 — Updated to the 2024 ADA/EASD consensus on hyperglycemic crises: DKA defined by glucose ≥200 mg/dL (or known diabetes) with β-hydroxybutyrate ≥3.0 mmol/L preferred over urine ketones; euglycemic DKA (e.g., with SGLT2 inhibitors) recognized.
    • 
        
  • Jun 2026 — Revised treatment targets: add dextrose at glucose <250 mg/dL with insulin 0.05 units/kg/h; replace potassium once K+ <5.0 (hold insulin if <3.5); resolution defined by β-hydroxybutyrate <0.6 mmol/L with pH ≥7.3 (anion gap no longer used).
    • 
        
  • Jun 2026 — Corrected the ADA Standards of Care hospital-care reference and added the 2024 consensus report as the primary source.
    • 
      

      
Umpierrez GE, Davis GM, ElSayed NA, et al. Hyperglycemic Crises in Adults With Diabetes: A Consensus Report. Diabetes Care. 2024;47(8):1257-1275. PMID 39052901.


      
Key Knowledge Points

      
    
        
  • 
          This DKA & HHS Treatment Guideline prioritizes
          fluid resuscitation,
          insulin therapy, and
          potassium management.
        
    • 
        
  • 
          Fluids first: Aggressive IV hydration with
          0.9% NaCl or a balanced crystalloid (e.g., LR) is the
          initial step to restore volume.
        
    • 
        
  • 
          Check Potassium (K+) BEFORE starting insulin. If K+
          is <3.5 mmol/L, do NOT start insulin; replete K+ first to prevent
          life-threatening arrhythmia.
        
    • 
        
  • 
          An IV insulin infusion is the standard of care. A bolus is no longer
          routinely recommended in adults for DKA.
        
    • 
        
  • 
          Treat the underlying precipitating cause (e.g., infection,
          non-compliance, MI).
        
    • 
        
  • 
          Transitioning to subcutaneous insulin is a high-risk step and requires
          a 1-2 hour overlap with the IV insulin infusion to prevent rebound
          ketoacidosis.
        
    • 
      

    


    

      
About This DKA & HHS Treatment Guideline Tool

      

        This interactive tool is designed to assist healthcare professionals in
        navigating the complex, time-sensitive management of Diabetic
        Ketoacidosis (DKA) and Hyperosmolar Hyperglycemic State (HHS). These are
        life-threatening endocrine emergencies requiring prompt, protocol-driven
        care. This guide simplifies the
        DKA & HHS Treatment Guideline by breaking it down into
        critical steps.
      


      
Diagnostic Criteria: DKA vs. HHS

      

        
          

            Parameter
            DKA
            HHS
          

        
        
          

            Plasma Glucose
            ≥200 mg/dL, or known diabetes*
            >600 mg/dL
          

          

            Arterial pH
            <7.30
            >7.30
          

          

            Serum Bicarbonate
            <18 mEq/L
            >18 mEq/L
          

          

            Urine/Serum Ketones
            β-hydroxybutyrate ≥3.0 mmol/L (preferred)
            Small or negative (<3.0 mmol/L)
          

          

            Anion Gap
            >10-12 (supportive only)
            Variable
          

          

            Serum Osmolality
            Variable
            >300 mOsm/kg (effective)
          

        
      

      
* Euglycemic DKA (glucose <200 mg/dL) can occur, especially with SGLT2 inhibitors, pregnancy, or poor oral intake. The 2024 consensus prefers blood β-hydroxybutyrate over urine ketones, and a mild/moderate/severe severity grade based on pH/bicarbonate and ketonemia.


      
Detailed Management Principles

      
1. Fluid Resuscitation

      

        This is the most critical first step. The goal is to correct
        intravascular volume depletion, improve renal perfusion, and lower serum
        glucose. Recent guidelines suggest balanced crystalloids are a reasonable
        alternative to normal saline.
      

      
    
        
  • 
          Initial (First Hour): Infuse 1 to 1.5 Liters of
          0.9% NaCl or
          Balanced Crystalloid Solution (e.g., Lactated Ringer’s).
        
    • 
        
  • 
          Subsequent: After the first hour, calculate the
          corrected serum sodium.
          
      
            
    • 
              If corrected Na+ is high/normal: Switch to
              0.45% NaCl at 250-500 mL/hr.
            
      • 
            
    • 
              If corrected Na+ is low: Continue
              0.9% NaCl (or balanced crystalloid) at 250-500
              mL/hr.
            
      • 
          
    
        
    • 
        
  • 
          Adding Dextrose: When serum glucose reaches
          <250 mg/dL (DKA) or
          ~300 mg/dL (HHS), add
          5–10% dextrose and reduce the insulin infusion to
          0.05 units/kg/h to prevent hypoglycemia while clearing ketones.
        
    • 
      


      
2. Insulin Therapy

      

        Insulin is essential to stop ketogenesis and correct hyperglycemia.
        NEVER start insulin until serum K+ is ≥3.5 mmol/L.
      

      
    
        
  • 
          Standard Dose: Start a continuous IV infusion of
          Regular Insulin at
          0.1 units/kg/hr.
        
    • 
        
  • 
          Titration: Aim for a glucose drop of 50-75 mg/dL per
          hour. If not achieved, the infusion rate may need to be adjusted.
        
    • 
        
  • 
          Note: A fixed-rate IV infusion is standard; an initial
          0.1 units/kg bolus is optional and mainly considered if IV access is delayed.
        
    • 
        
  • 
          Mild/moderate DKA: Per the 2024 consensus, subcutaneous
          rapid-acting insulin (e.g., lispro, aspart) every 1–2 hours is an acceptable
          alternative to an IV infusion in selected, non-severe cases that can be
          managed outside the ICU, using an institutional protocol.
        
    • 
      


      
3. Potassium (K+) Management

      

        Patients with DKA/HHS are total-body potassium depleted, even if their
        serum K+ is normal or high. Insulin therapy will drive K+ into cells,
        causing a rapid drop.
      

      
    
        
  • 
          If initial K+ is <3.5 mmol/L: HOLD insulin. Replace
          K+ at ~10 mmol/hr until K+ is ≥3.5 mmol/L.
        
    • 
        
  • 
          If initial K+ is 3.5-5.0 mmol/L: START insulin. Add
          20-30 mmol of K+ (as KCl and/or KPhos) to each liter of IV fluid, targeting K+ 4-5 mmol/L.
        
    • 
        
  • 
          If initial K+ is >5.0 mmol/L: START insulin. Do not
          add K+ initially; recheck within 2 hours and begin replacement once K+ <5.0 mmol/L.
        
    • 
      


      
Limitations

      

        This tool provides a general framework based on the
        DKA & HHS Treatment Guideline. It is not a substitute for
        clinical judgment. Patient-specific factors (e.g., renal failure,
        congestive heart failure, extremes of age) require careful modification
        of these protocols.
      


      
Frequently Asked Questions (FAQ)

      

        1. Why use balanced crystalloids (like LR) instead of normal saline
        (0.9% NaCl)?
      

      

        Normal Saline contains a high chloride load, which can cause or worsen a
        non-anion gap metabolic acidosis (hyperchloremic acidosis). This can
        confuse the clinical picture by keeping the bicarbonate low even as the
        ketoacidosis (anion gap) resolves. Balanced solutions (a key part of the modern DKA & HHS Treatment Guideline)
        have a more physiologic chloride concentration and may lead to
        a faster resolution of acidosis.
      


      

        2. When and why do I add dextrose (D5W) to the IV fluids?
      

      

        Add dextrose when serum glucose reaches <250 mg/dL (DKA) or ~300 mg/dL
        (HHS), and reduce the insulin infusion to 0.05 units/kg/h. The goal of insulin therapy is to stop ketone production (i.e.,
        “close the anion gap”), not just to normalize glucose. Adding dextrose
        allows you to continue the insulin infusion to resolve the acidosis
        without making the patient hypoglycemic.
      


      
3. When should bicarbonate be given?

      

        Bicarbonate therapy is rarely indicated. Most guidelines
        recommend considering it
        only if the arterial pH is <7.0. In this severe
        acidosis, give 100 mmol of sodium bicarbonate over 2 hours. It is not
        recommended for pH ≥7.0, as insulin therapy and fluids will correct
        the acidosis.
      


      

        4. What are the criteria for “resolution” of DKA?
      

      

        DKA is considered resolved when the patient meets all of the following:
β-hydroxybutyrate <0.6 mmol/L and venous pH ≥7.3 (or serum
        bicarbonate ≥18 mmol/L); the serum anion gap is no longer recommended for
        assessing resolution because hyperchloremic acidosis can keep it elevated.
        HHS resolution is primarily defined by normal effective osmolality and mental
        status. The DKA & HHS Treatment Guideline stresses that all
        criteria must be met.
      


      

        5. How do I safely transition from an IV insulin drip to subcutaneous
        (SubQ) insulin?
      

      

        This is a critical step. Once DKA is resolved and the patient can eat,
        initiate their home-dose or weight-based long-acting (basal) SubQ
        insulin. CRITICAL: You must continue the IV insulin
        infusion for 1-2 hours AFTER the subcutaneous basal
        insulin is given to allow it to take effect. Stopping the IV drip
        before this overlap will result in rebound hyperglycemia and
        ketoacidosis. This is a key part of any DKA & HHS Treatment Guideline.
      


      
Related Calculators

      

      

        
📖 Sources:

        
    
          
  1. 
            Umpierrez GE, Davis GM, ElSayed NA, et al. (2024). Hyperglycemic
              Crises in Adults With Diabetes: A Consensus Report.
              Diabetes Care, 47(8), 1257–1275. PMID 39052901.
          
    2. 
          
  2. 
            American Diabetes Association. (2024). 16. Diabetes Care in the
              Hospital: Standards of Care in Diabetes—2024.
              Diabetes Care, 47(Suppl 1), S295–S306. PMID 38078585.
          
    3. 
          
  3. 
            Kitabchi, A. E., Umpierrez, G. E., Miles, J. M., & Fisher, J. N.
              (2009). Hyperglycemic Crises in Adult Patients With Diabetes.
              Diabetes Care, 32(7), 1335–1343.
          
    4. 
          
  4. 
            Dhatariya, K. K., Glaser, N. S., Codner, E., & Umpierrez, G. E.
              (2020). Diabetic ketoacidosis.
              Nature Reviews Disease Primers, 6(1), 40.
          
    5. 
        

      


      

        
⚠️ Disclaimer:

        

          This tool is for informational and educational purposes only and is not
          a substitute for professional clinical judgment. This
          DKA & HHS Treatment Guideline tool is an aid, not a
          replacement for clinical expertise. All treatment decisions must be
          made by a qualified healthcare professional considering the individual
          patient’s full clinical context.
        

      

    


    

      DosePilot Logo
      

        Powered by
        DosePilot.com
      

    

  





			


				





	

					

				
Infective Endocarditis Treatment Guideline
			

			

						
						
							Interface of the Infective Endocarditis Treatment Guidelines showing selection buttons with gray bars for unselected and blue bars for selected items
						
					

			

				














💊 Infective Endocarditis Treatment Guidelines


2023 ESC / 2015 AHA Guideline-Directed Therapy


Reviewed by the DosePilot Medical Team · Last medically reviewed: June 2026









1. Valve Type














2. Organism
Based on culture results


















3. Details
Susceptibility & Setting


















4. Penicillin Allergy?
Severe / Anaphylaxis

















Recommended Regimen




Please select all options above to see the recommended regimen based on Infective Endocarditis Treatment Guidelines.








Recent Updates


    

  • Jun 2026 — Updated to the 2023 ESC endocarditis guideline: aminoglycosides are no longer recommended for native-valve staphylococcal IE; rifampin is reserved for prosthetic material and added only after 3–5 days once bacteremia clears; for MSSA, cefazolin and cloxacillin are co-first-line with antistaphylococcal penicillins.
    • 

  • Jun 2026 — High-dose daptomycin (≥10 mg/kg/day, with a second agent) is an established guideline alternative to vancomycin for MRSA/staphylococcal IE.
    • 

  • Jun 2026 — Oral step-down (POET trial; ESC Class IIa): stabilized left-sided IE (streptococci, S. aureus, E. faecalis, CoNS) may switch to oral antibiotics after ≥10 days of IV therapy with endocarditis-team follow-up.
    • 



Delgado V, et al. 2023 ESC Guidelines for the management of endocarditis. Eur Heart J. 2023;44(39):3948-4042. PMID 37622656.


Clinical Pearls


    

  • Duration: Per Infective Endocarditis Treatment Guidelines, count days from the first negative blood culture.
    • 

  • Prosthetic Valves: Generally require longer treatment (min. 6 weeks) and often combination therapy (Rifampin for Staph) to penetrate biofilm.
    • 

  • Gentamicin: Use Ideal Body Weight (IBW) for dosing. Monitor renal function closely.
    • 

  • Rifampin: Never start alone or in the initial bacteremic phase to prevent rapid resistance emergence. Start 3-5 days after Vancomycin/Gentamicin clearance of bacteremia in PVE.
    • 

  • MSSA first-line: Antistaphylococcal penicillins (nafcillin/oxacillin) or cefazolin 2 g IV q8h are co-equal first-line (cloxacillin is the ESC equivalent). For MRSA or severe penicillin allergy, use vancomycin or high-dose daptomycin (8–10 mg/kg IV q24h, with a second agent).
    • 

  • Enterococci: Confirm the isolate is not high-level aminoglycoside-resistant (HLAR) before adding gentamicin — for HLAR E. faecalis use ampicillin + ceftriaxone; vancomycin-resistant E. faecium needs daptomycin or linezolid (ID consultation).
    • 







About These Infective Endocarditis Treatment Guidelines


This interactive guide provides antibiotic regimens derived from the 2023 ESC (European Society of Cardiology) endocarditis guideline and the 2015 AHA (American Heart Association) scientific statement. It simplifies the complexity of selecting regimens based on valve type, pathogen, and resistance patterns.

👉 Need Diagnosis? Use Modified Duke Criteria
👉 Need Dosing Info? Check Antibiotic Dosing Guide

Antibiotic Pharmacology & Mechanisms


To effectively utilize these Infective Endocarditis Treatment Guidelines, understanding the underlying antibiotic pharmacology is key:


    

  • Vancomycin:

    Mechanism: Inhibits cell wall synthesis.

    Role in IE: The backbone of therapy for MRSA and patients with severe penicillin allergy. It is bactericidal but kills Staphylococci slower than beta-lactams (like Nafcillin).
    • 

  • Gentamicin (Aminoglycosides):

    Mechanism: Inhibits protein synthesis (30S ribosome).

    Role in IE: Used for synergy. By itself, it has poor penetration, but when cell walls are damaged by Penicillin/Vancomycin, Gentamicin enters and rapidly kills the bacteria. Crucial for Enterococci and Streptococci with higher MICs.
    • 

  • Rifampin:

    Mechanism: Inhibits RNA polymerase.

    Role in IE: Unique ability to penetrate biofilms and kill dormant (non-dividing) Staphylococci adhering to prosthetic material. Essential for Prosthetic Valve Endocarditis (PVE).
    • 

  • Ceftriaxone (in Enterococcal IE):

    Mechanism: 3rd generation Cephalosporin.

    Role in IE: In E. faecalis, it saturates specific penicillin-binding proteins (PBPs) that Ampicillin misses. This “Double Beta-Lactam” strategy offers similar synergistic killing to Gentamicin but with significantly lower nephrotoxicity.
    • 



Frequently Asked Questions (FAQ)


1. When should surgery be considered?


According to Infective Endocarditis Treatment Guidelines, early surgery is indicated for: Heart failure due to valve dysfunction, uncontrolled infection (abscess, enlarging vegetation >10mm, persistent fever), or prevention of embolism.


2. How long is the treatment duration?


Standard duration is 4 to 6 weeks, counted from the first negative blood culture. Native-valve Strep infection can sometimes be treated in 2 weeks with combination therapy. Prosthetic valve infections always require at least 6 weeks. In stabilized left-sided IE, the 2023 ESC guideline supports oral step-down (POET trial) after at least 10 days of IV therapy with endocarditis-team oversight.


3. What if the patient has a non-severe Penicillin allergy?


For MSSA or Strep, Cefazolin is often the drug of choice in patients with non-anaphylactic penicillin allergies. Vancomycin is reserved for severe (Type 1) allergies or MRSA.


4. Why is Rifampin added for Prosthetic Valve Staph IE?


Staphylococci form a biofilm on prosthetic material. Rifampin is unique in its ability to penetrate this biofilm and kill dormant bacteria, significantly improving cure rates.


5. Is Gentamicin needed for Native Valve Staph?


Current Infective Endocarditis Treatment Guidelines do not recommend adding Gentamicin for Native Valve S. aureus endocarditis due to increased nephrotoxicity without proven mortality benefit.


6. What are the alternatives to vancomycin for MRSA endocarditis?


The 2023 ESC guideline endorses high-dose daptomycin (≥10 mg/kg/day), generally combined with a second agent (e.g., cloxacillin or fosfomycin), as an alternative to vancomycin for MRSA or staphylococcal IE — particularly when the vancomycin MIC is elevated or tolerability is a concern.


Related Calculators





📖 Sources:


    

  1. Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC Guidelines for the management of endocarditis. Eur Heart J. 2023;44(39):3948-4042. DOI:10.1093/eurheartj/ehad193. PMID 37622656.
    2. 

  2. Baddour LM, Wilson WR, Bayer AS, et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation. 2015;132(15):1435-1486. PMID 26373316.
    3. 

  3. Iversen K, Ihlemann N, Gill SU, et al. Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis (POET). N Engl J Med. 2019;380(5):415-424. PMID 30152252.
    4. 

  4. Fowler VG, Durack DT, Selton-Suty C, et al. The 2023 Duke-ISCVID Criteria for Infective Endocarditis. Clin Infect Dis. 2023;77(4):518-526. PMID 37138445.
    5. 







⚠️ Disclaimer:


This tool aggregates recommendations from standard Infective Endocarditis Treatment Guidelines for informational purposes only. Antibiotic selection requires consideration of local resistance patterns, renal function, and specific patient factors. Always consult an Infectious Disease specialist.







DosePilot Logo

Powered by DosePilot.com








			


				





	

					

				
CRE Management Guideline
			

			

						
						
							CRE management guide in action - interactive clinical decision tool showing type-specific recommendations and renal dosing guidance
						
					

			

				











    

        
🛡️ CRE Management Guide

        
Evidence-Based Tool for Carbapenem-Resistant Enterobacterales (CRE)

        
Reviewed by the DosePilot Medical Team · Last medically reviewed: June 2026

    


    

        
        

            
            
        

    


    

    

    


    

        
Recommended Management Strategy

        

        

            Note: Doses shown are for normal renal function.

            Always adjust based on patient CrCl.

            📋 Refer to our Antibiotic Dosing Guide for precise renal dosing adjustments.
        

    


    

    

        
Recent Updates

        
    
            
  • Jun 2026 — For OXA-48-like CRE, ceftazidime-avibactam is preferred and cefiderocol is the alternative; meropenem-vaborbactam and imipenem-relebactam are not reliable against OXA-48 (their inhibitors do not cover OXA-48).
    • 
            
  • Jun 2026 — For NDM/metallo-β-lactamase producers, preferred options are ceftazidime-avibactam + aztreonam or cefiderocol; aztreonam-avibactam is now a validated option (REVISIT trial). Polymyxin/tigecycline combinations are reserved for last resort.
    • 
            
  • Jun 2026 — Once an active β-lactam (or cefiderocol) is identified, routine addition of a second agent is not recommended (IDSA 2024); the only endorsed combination is ceftazidime-avibactam + aztreonam to restore activity against metallo-β-lactamases.
    • 
        

        
Tamma PD, Heil EL, Justo JA, et al. IDSA 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin Infect Dis. 2024. PMID 39108079.


        
Key Knowledge Points

        
    
            
  • This CRE management guide aligns with the latest IDSA 2024 recommendations, prioritizing novel agents for susceptible isolates.
    • 
            
  • CRE colonization requires strict contact precautions but no antibiotic treatment unless infection develops.
    • 
            
  • Source control (e.g., device removal, drainage) is essential and often more impactful than antibiotics alone.
    • 
            
  • Novel agents like ceftazidime-avibactam are preferred for KPC and OXA-48; aztreonam combinations for NDM-producing CRE.
    • 
            
  • Combination therapy is reserved for severe cases; monotherapy preferred when possible to reduce toxicity.
    • 
        

    


    

        
About This CRE Management Guide

        
The CRE management guide is an interactive decision support tool designed for infectious disease specialists, critical care teams, pharmacists, and infection preventionists managing carbapenem-resistant Enterobacterales (CRE) cases. With mortality rates often exceeding 40% in invasive infections, timely and accurate management is crucial. This CRE management guide incorporates the most recent IDSA 2024 guidance, emphasizing susceptibility-driven therapy, source control, and antimicrobial stewardship to combat rising resistance. It includes carbapenemase type selection (KPC, NDM, OXA-48-like) for refined recommendations, promoting novel beta-lactam/beta-lactamase inhibitors as first-line when active.

        
The CRE management guide supports clinicians in high-burden settings by providing clear hierarchies for colonization versus infection, while stressing the importance of local epidemiology and infectious diseases consultation.


        
How to Use This CRE Management Guide

        
1. Select patient status (colonization or infection).
2. For infections, choose primary site and carbapenemase type.
3. View tailored recommendations instantly.
4. Use Key Knowledge Points for rapid reference.
5. Always confirm with susceptibility results, local protocols, and specialist input.


        
Clinical Interpretation & Limitations

        
Interpretation: Therapy is carbapenemase-directed. For KPC, ceftazidime-avibactam, meropenem-vaborbactam, or imipenem-relebactam are all active. For OXA-48-like, ceftazidime-avibactam is preferred and cefiderocol is the alternative — meropenem-vaborbactam and imipenem-relebactam are not reliable against OXA-48. For NDM/metallo-β-lactamase producers, use ceftazidime-avibactam + aztreonam, cefiderocol, or aztreonam-avibactam. Monotherapy with a single active β-lactam is preferred for susceptible isolates per IDSA 2024; routine addition of a second agent adds toxicity without proven benefit (the CAZ-AVI + aztreonam pairing is the exception, used to restore activity against metallo-β-lactamases). Duration: 7-14 days for uncomplicated infection, longer for complex or undrained sources. Monitor toxicity closely.

        
Limitations: This CRE management guide offers general evidence-based suggestions and does not replace clinical judgment or real-time susceptibility data. Doses are baseline—renal dosing adjustments are required.


        
Frequently Asked Questions (FAQ)

        
1. What defines CRE in this CRE management guide?

        
CRE are Enterobacterales resistant to any carbapenem or producing a carbapenemase (e.g., KPC, NDM, OXA-48).


        
2. Is combination therapy always required?

        
No—IDSA 2024 prefers monotherapy for susceptible CRE to minimize toxicity; combinations for severe or resistant cases.


        
3. How does carbapenemase type affect therapy?

        
KPC: ceftazidime-avibactam, meropenem-vaborbactam, or imipenem-relebactam. OXA-48-like: ceftazidime-avibactam preferred, with cefiderocol as the alternative (vaborbactam and relebactam do not cover OXA-48). NDM/metallo-β-lactamase: ceftazidime-avibactam + aztreonam, cefiderocol, or aztreonam-avibactam.


        
4. Is inhaled colistin recommended for CRE pneumonia?

        
Not routinely—current IDSA guidance does not endorse adjunctive inhaled antibiotics for CRE pneumonia due to limited evidence.


        
5. How should renal impairment be handled?

        
All recommended agents require dose adjustment in renal impairment. Refer to our Antibiotic Dosing Guide for precise adjustments.


        
6. When to consult ID specialists?

        
Always for confirmed CRE infections, per CRE management guide recommendations.


        
Related Calculators

        

        

            
📖 Sources:

            
    
                
  1. Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin Infect Dis. 2024. DOI:10.1093/cid/ciae403. PMID 39108079.
    2. 
                
  2. Carmeli Y, Cisneros JM, Paul M, et al. Aztreonam-avibactam versus meropenem for serious infections caused by Gram-negative bacteria (REVISIT): a phase 3 randomised trial. Lancet Infect Dis. 2025;25(2):218-230. PMID 39389071.
    3. 
                
  3. Bassetti M, Echols R, Matsunaga Y, et al. Cefiderocol or best available therapy for carbapenem-resistant Gram-negative infections (CREDIBLE-CR): a phase 3 trial. Lancet Infect Dis. 2021;21(2):226-240. PMID 33058795.
    4. 
                
  4. Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for carbapenem-resistant Gram-negative bacteria (AIDA): a randomised controlled trial. Lancet Infect Dis. 2018;18(4):391-400. PMID 29456043.
    5. 
                
  5. CDC. Facility Guidance for Control of Carbapenem-resistant Enterobacterales (CRE) — CRE Toolkit.
    6. 
            

        


        

            
⚠️ Disclaimer:

            
This tool is for informational and educational purposes only and is not a substitute for professional clinical judgment. All treatment decisions must be made by a qualified healthcare professional considering the individual patient’s full clinical context.

        

    


    

        DosePilot Logo
        
Powered by DosePilot.com